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Sera from patients with thyroid disorders or diabetes were
tested for the presence of soluble immune complexes using a number
of established or modified assay systems. In addition, a new and
sensitive assay for the detection of complexes was developed.
The first assay system applied was based on the inhibition of
the antibody-dependent cell-mediated cytotoxic (ADCC) activity of
rat spleen cells by soluble complexes which compete with antibody-
coated target cells for Fc receptors on the effector cells. The
sensitivity of this assay was found to be approximately 25pg/ml of
added aggregated IgG.
The Clq deviation test, an assay based on the deviation of
binding of radiolabelled Clq to sensitized sheep erythrocytes by
immune complexes, was found to be insufficiently sensitive or
reproducible and accordingly rejected.
The Raji cell radioimmunoassay, which relies on the binding of
complexes to complement receptors on Raji cells and the subsequent
detection of radiolabelled anti-human IgG antibody bound to the cells,
was found to have a sensitivity of 6pg/ml added aggregates. By
referring to a standard curve of radiolabelled antibody uptake by
cells previously incubated with varying amounts of aggregates, it was
possible to quantitate the complexes detected in test sera. A
modification of the assay using radiolabelled anti-human thyroglobulin
antibody instead of radiolabelled anti-IgG antibody was used to
characterize the complexes detected in the sera from patients with
thyroid disorders.
A new sensitive•and reproducible assay was developed during
this study. This method, the rat spleen leucocyte (RSL) radioimmuno¬
assay, is based on the binding of complexes to rat spleen leucocytes
via Fc receptors and the subsequent detection of radiolabelled
anti-human IgG bound to the cells. The sensitivity of this assay
was found to be Ajig/ml added aggregates. The complexes were
quantitated by referring to a standard curve of radiolabelled antibody
uptake by cells previously incubated with varying amounts of aggregated
IgG. The results obtained using this assay were compared with those
obtained using the Raji cell radioimmunoassay.
Using the ADCC inhibition assay, 17 out of 25 Hashimoto, 15 out
of 29 hypothyroid, 8 out of 26 untreated thyrotoxic and 12 out of 27
treated thyrotoxic sera were found to be positive for the presence of
immune complexes. The degree of inhibition could not be correlated
with levels of serum IgG. In particular, the inhibitory activity of
Hashimoto sera could not be attributed to the high levels of IgG found
in these sera.
Using the Raji cell radioimmunoassay, 18 out of 23 Hashimoto, 10
out of 28 hypothyroid and A out of 20 untreated thyrotoxic sera were
found to be positive for the presence of immune complexes.
Thyroglobulin was demonstrated to be a component of the immune
complexes detected in 8 out of 18 positive Hashimoto and 3 out of 10
positive hypothyroid sera. No correlation was found between the
presence and titre of anti-thyroid antibodies and the presence of
complexes by either the ADCC inhibition assay or the Raji cell
radioimmunoassay.
The Raji cell radioimmunoassay was also used to detect and
quantitate immune complexes in the sera of diabetics. 7 out of 13
newly diagnosed insulin-dependent diabetics were found to be positive.
Islet cell antibodies were detected in 6 of the positive sera but in
none of the negative sera. The titres for a wide range of viral
antibodies were found to be similar in these 13 diabetic patients and
in their age- and sex-matched controls. 17 out of 32 diabetics
treated with insulin and 5 out of 52 diabetics requiring oral
hypogiycaemic agents or restrictions of diet had evidence of immune
complexes in their serum. Hightitres of insulin antibodies in the
sera of insulin-treated diabetics were found to correlate with the
presence of immune complexes. In addition, there was a tendency for
immune complexes to occur in the presence of moderate titres of
insulin antibodies when the age at onset of insulin-dependent diabetes
was less than 30 years. Out of 16 patients treated with insulin for
13 years or more, with late diabetic complications, 12 had immune
complexes in their serum.
In both patients with thyroid disorders and those with diabetes,
the results using the RSL radioimmunoassay were comparable to those
obtained using the Raji cell radioimmunoassay. In general, the
amount of complexes detected in a given serum was lower in the RSL
than in the Raji cell radioimmunoassay. The RSL assay was also used
to demonstrate that heat treatment of normal human serum induces the
formation of aggregates.
The significance of these observations on the presence of
circulating immune complexes in sera of patients with thyroid disorders
and diabetes mellitus is discussed in relation to the possible role
of these complexes in the pathogenesis of autoimmune disorders.
LIST OF TABLES
Table 1: Percentage inhibition of ADCC by sera from patients with
thyroid disorders.
Table 2: Serum IgG levels of patients with thyroid disorders.
Table 3: Correlation between percentage inhibition of ADCC by sera
from patients with Hashimoto thyroiditis and clinical data.
Table A: Correlation between percentage inhibition of ADCC by sera
from patients with primary hypothyroidism and clinical data.
Table 5: Correlation between percentage inhibition of ADCC by sera
from patients with untreated thyrotoxicosis and clinical
data.
Table 6: Correlation between percentage inhibition of ADCC by sera
from patients with treated thyrotoxicosis and clinical data.
Table 7: Detection and quantitation of immune complexes in sera
of patients with thyroid disorders using the Raji cell
radioimmunoassay.
Table 8: The binding of complexes to untreated Raji cells and to
Raji cells pretreated with normal rabbit serum.
Table 9: Correlation between the presence of complexes detected
by the Raji cell radioimmunoassay in the sera of patients
with Hashimoto thyroiditis and clinical data.
Table 10: Correlation between the presence of complexes detected by
the Raji cell radioimmunoassay in the sera of patients with
primary hypothyroidism and clinical data.
Table 11: Correlation between the presence of complexes detected by
the Raji cell radioimmunoassay in the sera of patients
with thyrotoxicosis and clinical data.
Table 12: Detection and quantitation of immune complexes in diabetic
sera using the Raji cell radioimmunoassay.
Table 13: Anti-viral antibodies in sera of newly-diagnosed insulin-
dependent diabetics.
Table 14: Inhibition of binding of complexed human IgG to RSL by
aggregated autologous rat IgG.
Table 15: Detection and quantitation of immune complexes in sera
from patients with thyroid disorders and diabetics using
the RSL and Raji cell radioimmunoassays.
LIST OF FIGURES
Figure 1: The cytotoxic indices at various effector/target cell
ratios using two different concentrations of anti-CRBC
antiserum.
Figure 2: The cytotoxic indices at two effector/target cell ratios
using various dilutions of anti-CRBC antiserum.
Figure 3: Percentage inhibition of ADCC by ovalbumin -antiovalbumin
complexes.
Figure A: Percentage inhibition of ADCC by various concentrations of
aggregated IgG.
Figure 5: Percentage inhibition of ADCC by various concentrations of
aggregated IgG in different dilutions of serum.
Figure 6: Percentage inhibition of ADCC by serial dilutions of heat
inactivated normal serum using two effector/target cell
ratios.
Figure 7: Correlation of percentage inhibition of ADCC by sera from
patients with Hashimoto thyroiditis and hypothyroidism with
the IgG levels of these sera.
Figure 8: Correlation of percentage inhibition of ADCC by sera from
patients with thyrotoxicosis with the IgG levels of these
sera.
Figure 9: Correlation of inhibition of ADCC by sera from patients
with Hashimoto thyroiditis and their controls with IgG
levels.
Figure 10: Correlation of inhibition of ADCC by sera from patients
with primary hypothyroidism and their controls with IgG
levels.
Figure 11: Correlation of inhibition of ADCC by sera from patients
with untreated thyrotoxicosis and their controls with
IgG levels.
Figure 12: Correlation of inhibition of ADCC by sera from patients
with treated thyrotoxicosis and their controls with
IgG levels.
Figure 13: Chromatography of Hashimoto and control sera on Sephadex
G-200 showing the IgG content and the percentage inhibition
of ADCC associated with each fraction.
Figure 14: Chromatography of heat-inactivated Hashimoto and control
sera on Sephadex G-200 showing the percentage inhibition
of ADCC associated with each fraction.
Figure 1 5: Chromatography of sera from a patient with primary
hypothyroidism and its control on Sephadex G-200 showing
IgG content and the percentage inhibition of ADCC
associated with each fraction.
Figure 16: Deviation of radiolabelled Clq from binding to sensitized
sheep erythrocytes by various amounts of aggregated IgG
added to normal human serum.
Figure 17: Deviation of radiolabelled Clq from binding to sensitized
sheep erythrocytes by various amounts of aggregated IgG
added to each of five normal human sera.
Figure 18: The DEAE cellulose separation profile of goat anti-human
IgG antiserum.
Figure 19: Titration of radiolabelled anti-human IgG for the
demonstration of aggregated IgG in serum: Raji cell
radioimmunoassay.
Figure 20: Standard curve of radiolabelled anti-human IgG bound to
untreated or NRS-treated Raji cells incubated with various
amounts of aggregated IgG.
Figure 21: The binding of radiolabelled anti-human thyroglobulin
antibodies to Raji cells pre-incubated with sera from
patients with thyroid disorders.
Figure 22: Correlation between the occurrence of immune complexes
and insulin antibodies in the thirty-two insulin-treated
diabetics and the duration of insulin treatment.
Figure 23: Correlation between the titre of insulin antibodies and
the amount of immune complexes in sera from thirty-two
insulin-treated diabetics.
Figure 2A: The prevelance of immune complexes and titres of insulin
antibodies in insulin-treated diabetics according to the
age at onset of the diabetes.
Figure 25: Correlation between the amount of immune complexes and
the presence of late diabetic complications according to
the duration of diabetes in the thirty-two insulin-treated
patients.
Figure 26: The uptake of radiolabelled anti-human IgG by various
concentrations of RSL incubated with different amounts of
aggregated IgG.
Figure 27: The uptake of radiolabelled anti-human IgG by RSL incubated
with different volumes of normal human serum containing
various amounts of aggregated IgG.
Figure 28: Titration of radiolabelled anti-human IgG for the
demonstration of aggregated IgG in serum: RSL
radioimmunoassay.
Figure 29: The uptake of radiolabelled anti-human IgG by RSL incubated
with various amounts of aggregated IgG: the effect of
different incubation times.
Figure 30: Inactivation of normal human serum with various
concentrations of EDTA as shown by the effect on binding
of a fixed amount of aggregated IgG (16pg/ml) to RSL.
Figure 31 : Standard curve of radiolabelled anti-human IgG bound to
RSL incubated with various amounts of aggregated IgG
added to serum or medium.
Figure 32: The uptake of radiolabelled anti-human IgG by RSL
incubated with medium or with serum containing aggregated
IgG: the effect of inactivation by EDTA or EGTA.
Figure 33: The effect of fresh, heat-inactivated and EDTA treated
serum on the aggregates bound to RSL.
Figure 34: The uptake of radiolabelled anti-human IgG by RSL
incubated with normal human sera: the effect of heat-
inactivation of the sera.




1.1. GENERAL: THE ROLE OF IMMUNE COMPLEXES IN DISEASE
2
Early in this century two different phenomena attracted the
attention of the clinicians. The first was observed by Arthus (1903),
who undertook an experiment with horse serum injected to animals.
The first injection was found to effect the animals in such a
manner that repeated injections were very dangerous. Von Pirquet
(1911) observed that a single injection of horse serum which was used
as a source of antitoxin in the treatment of diphtheria, tetanus,
scarlet fever and epidemic meningitis, sometimes caused symptoms to
which he gave the name of serum sickness. It was suggested that the
symptoms were due to the formation of antibody to the injected material.
An analogy between serum sickness and clinical events such as urticaria,
hay fever, post scarlet fever nephritis, tuberculosis, syphilis, and
actinomycosis was also suggested by Von Pirquet.
The observations of Longcope and Rackemann (1918), and those of
Mackenzie and Leake (1921) on the morphological lesions which developed
in humans receiving therapeutic serum lead them to suggest the
involvement of antigen-antibody reactions within the circulation or on
tissue cells. Rich and Gregory (1943), Hoppes and Wissler (1946),
Rich (1947) and Ehrich and associates (1949), using animal models,
demonstrated the effects of antigen-antibody reactions resembling those
occurring in human diseases such as rheumatic fever, rheumatoid
arthritis, glomerulonephritis, disseminated lupus erythematosus and
polyarteritis nodosa.
Hawn and Janeway (1947) injected purified serum proteins into
rabbits and demonstrated lesions similar to those induced using whole
serum. They concluded that the lesions of serum sickness did indeed
develop at the time of antigen-antibody interaction. Similar findings
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were also reported by Germuth in 1953, who described an "immune phase"
of antigen elimination in which all tissue lesions developed as a
result of antigen-antibody combination.
The pathogenic mechanisms by which antigen-antibody reactions
lead to tissue injury were not clearly defined. One concept was that
the damage was caused by the reaction of antibody with the target
tissue. This derived from the experiments of Lindemann (1900),
Pearce (1903) and Smadel (1936) who used heterologous anti-kidney
serum to produce experimental nephritis resembling glomerulonephritis
in man. It is unlikely that this mechanism operates since although
humoral antibody may induce damage to circulating cells or cells in
monolayer (endothelium and vascular basement membrane), there is no
evidence that solid tissue can be affected (Waksman, 1962). The
alternative concept was that of Von Pirquet (1911), who ascribed the
phenomenon of serum sickness to the formation of a toxic compound by
antibody combined with the foreign serum antigen.
Germuth and McKinnon in 1957 demonstrated that soluble antigen-
antibody complexes by themselves were pathogenic agents as features of
anaphylactic shock could be elicited by injecting unsensitized guinea-
pigs with these complexes. Tokuda and Weiser (1958) reported similar
results using mice. Weigle and co-workers (1960) confirmed these
results in guinea-pigs and rabbits. Similar findings were reported
earlier by Dean and co-workers (1936), using intravenous injections of
antigen immediately after an intravenous injection of antiserum.
Using isotopically labelled antigens, soluble antigen-antibody
complexes could be demonstrated in the circulation during experimental
serum sickness (Dixon, 1957). The development of the morphological
manifestation of serum sickness could be shown to be accompanied by an
almost simultaneous localization of antigen and in some cases antibody
A
in the site of the lesion, but there was no detectable localization
or fixation of antigen in the tissue predisposed to the development of
lesion prior to the formation of antibody (Dixon et al., 1958).
Many workers have used a variety of techniques in order to
establish the pathogenicity of complexes. The early work of Kulka
(1942) showed that antigen-antibody mixtures induce smooth muscle
contraction and that this effect depends on a quantitative relationship
between antigen and antibody. Similar results were demonstrated by
Trapani and co-workers (1958), who found that only complexes in slight
to moderate antigen excess were active in inducing smooth muscle
contraction in vitro.
The induction of increased cutaneous vascular permeability by
complexes was used by Ishizaka and associates (ishizaka and Campbell,
1958, 1959; Ishizaka et al., 1959a, b) to study the molecular
characteristics of the pathogenic complexes. These authors were able
to conclude that the activity of a complex depends upon its composition
with respect to antiger/an"tit)ody ratio and upon the properties of the
antibody and not the antigen. Human, rabbit and guinea-pig antibodies
but not bovine, chicken or horse could form active complexes. The
toxicity of complexes was due to a molecular change brought about in
either the antigen or antibody molecule as a result of combination.
The ability to fix complement depends on the properties of the antibodies
e.g. complexes of either horse or chicken antibodies do not fix
complement while rabbit antibodies have this ability. In addition
they found that human and rabbit IgG as well as inactive antigen-
antibody complexes inhibit the cutaneous permeability usually induced
by an active complex.
Ishizaka and Ishizaka (1959) demonstrated that heat-aggregated
human gammaglobulin induced increased vascular permeability and that
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the aggregates were comparable to antigen-antibody complexes on a
weight basis with respect to both skin reactivity and complement
fixation. Christian (1960b) found marked polymorphonuclear and
mononuclear infiltrations in the skin of guinea-pig, rat and man
injected with aggregated human gammaglobulin. In addition, the
intravenous injection of such aggregates, which were anticomplementry
in vitro, rendered the sera of recipient animals deficient in
haemolytically active complement for several hours.
Dixon (1962) suggested the possibility that aggregation of
gammaglobulin can occur in vivo as well as in vitro and could have the
same biological activity. If this can occur, gammaglobulin complex-
induced diseases may not necessarily have an immunological basis.
Other workers have investigated other aspects of the biological
activity of soluble immune complexes. Arocha and Mcllreath (1959)
reported the release of histamine from isolated guinea-pig lung or rat
small intestine when these tissues were perfused with soluble antigen-
antibody complexes. Mota in 1961 using a similar assay system could
not detect any damage to mast cells, and suggested that soluble
complexes do not act by preferentially releasing histamine from the
mast cells. Fibrinolysin was demonstrated to form In serum from its
inactive precursor by addition of complexes (Unger and Mist, 1949).
Lepow and co-workers (1956) showed that antigen-antibody aggregates
could convert the C1 component of complement present in fresh serum to
an active esterase. Antigen-antibody interaction in fresh serum was
associated with loss of haemolytic potency of the serum and the
appearance of anaphylotoxin as judged by its effect on capillary
permeability and smooth muscle contraction (Osier et al., 1959).
Many workers have studied the effects of complexes on a variety
of cell types. Using fluorescence and electron microscopic studies,
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Feldman in 1958 showed that antigen-antibody complexes initiated injury
to the endothelial cells of rabbit kidney glomeruli in serum sickness.
Miescher and Straessle (1956), and Straessle and Miescher (1956),
demonstrated that soluble antigen-antibody complexes agglutinate
leucocytes and that this effect depends upon the nature of the antigen
and antibody and upon the ratio of the two. Boyden (1962) demonstrated
that antigen-antibody mixtures were chemotactic to rabbit polymorpho¬
nuclear leucocytes in the presence of fresh but not heated serum. The
biological source of the test material was important in the initiation
of chemotaxis in that plant or bacterial protein were much more effective
than serum albumin of human or bovine origin. Immune complexes have
also been shown to induce the release of lysosomal material from
neutrophils (Hawkins and Peeters, 1971; Henson, 1971; Henson et al.,
1972).
It has been demonstrated that immune complexes induce platelet
aggregation (Siqueira and Nelson, 1961; Mueller-Eckhardt and Luscher,
1968) and the release of amines from platelets in the presence of plasma
(Gocke, 1965; Henson and Cochrane, 1969). Henson and Spiegelberg
(1973) demonstrated that human platelets bear receptors for the Fc
portion of immunoglobulin and that the platelets clump and release
nucleotides and vasoactive amines in response to immune complexes or
aggregated immunoglobulin.
Immune complexes have been found to enhance lymphocyte activation
as determined by morphological changes and the stimulation of DNA
synthesis (Bloch-Shtacher et al., 1968; Moller, 1969). Moller and
Lundgren (1968) reported that lymphocytes stimulated by antigen-antibody
mixtures of various types acquired cytotoxic activity against
fibroblasts of autochthonous and allogeneic origin.
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Pathological manifestations induced by complexes could result
from one or more of their demonstrated biological activities. The
simplest complex-induced lesion is the Arthus reaction, a localized
acute necrotizing vasculitis (Arthus, 1903; Arthus and Breton, 1903).
Opie (1924) demonstrated that this phenomenon occurs when an animal
immunized against a protein is reinjected with the same antigen and
occurs when antigen and antibody meet in the tissue. A similar reaction
was shown to occur at the site of injection when an injection of antigen
was followed by injection of serum from an immunized animal.
Cannon and Marshall (1941) found a definite parellelism between
the precipitating potency of the serum and the severity of cutaneous
reaction. Massive injections of antigen were shown to result in a
reduction of precipitin titre with a subsequent decrease or disappearance
of Arthus-type cutaneous hypersensitivity which later reappeared with
the rise in the titre.
Skin reactions marked by erythema, induration and occasionally
vascular haemorrhage and necrosis were demonstrated by the injection
of soluble antigen-antibody complexes intradermally (Cochrane and
Weigle, 1958). The lesions were also found to be similar in severity
to those resulting from the Arthus reaction, and it was concluded that
the presence of antigen-antibody complexes was responsible for the
reaction.
Local manifestations of the Arthus reaction were suggested to be
due to the accumulation of polymorphonuclear leucocytes in the area
of reaction, with intravascular aggregation of platelets and leucocytes
leading to thrombosis in the capillaries and veins. In addition, the
inflammatory necrotizing reaction failed to develop after the removal
of polymorphonuclear leucocytes from the circulation (Stetson, 1951).
Similar findings concerning polymorphs were reported by Humphrey
(1955a, b).
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Cochrane and co-workers (1959) demonstrated that polymorphonuclear
leucocytes play an essential role not only in producing the inflammatory
vasculitis, but also in ridding the damaged vessel of the antigen,
probably by means of proteolytic catabolism at the inflammatory site.
In the absence of these cells, antigen and antibody complexes were
deposited beneath the intima of small vessels without resulting
inflammation. Dixon (1962) reported that antigen-antibody precipitates
form by diffusion of antigen and antibody toward each other early in
the reaction and that these precipitates are chemotactic for
polymorphonuclear leucocytes. Within a few hours these cells infiltrate
the involved vessels which undergo necrosis. The cells phagocytose
the complex and carry it away from the site of the reaction.
The classical "one shot" serum sickness might be closer to the
situation in systemic human disease. Dixon and co-workers (1958)
using isotopically labelled antigens demonstrated the sequence of
immunological and morphological events occurring subsequent to the
injection of a large dose of serum protein antigen in rabbits. Three
distinct phases of removal of antigen from the circulation were
demonstrated. The equilibration of the intravenously injected foreign
protein between the intra- and extra-vascular serum protein pools
results in the first and sharpest fall. Next there is a non-
immunologically mediated catabolism of circulating free antigen at a
rate characteristic for the particular injected protein and the
recipient species. Finally there is a phase of rapid loss just
preceding the appearance of free circulating antibody. Once the
antibody forms, small complexes in an extreme antigen excess capable
of remaining in the circulation were formed. Antigen-antibody
complexes become larger as increasing amounts of antibody are formed
and are progressively removed from the circulation. Accompanying the
presence of complexes, there was a fall in serum complement levels and
the appearance of acute inflammatory lesions in the kidneys, heart,
arteries and joints resembling the lesions of acute glomerulonephritis
rheumatic fever, lupus erythematosus, polyarteritis nodosa, and
rheumatoid arthritis. Endothelial proliferation, increased vascular
permeability and infiltration of polymorphonuclear leucocytes were
elicited in varying degree in response to antigen-antibody complexes.
Dixon and co-workers (1961) extended the earlier work of McLean
and co-workers (1951) by injecting intravenously small amounts of
protein daily into rabbits, in order to mimic a chronic clinical
situation which might be produced by antigen-antibody complexes. It
was shown that the pathological events were of three types depending
upon the response. Firstly, there may be the production of a large
excess of antibody in the circulation which enables the animal to pass
from an antigen excess to an antibody excess environment with the
development of sizable amounts of antigen-antibody complexes in the
circulation. Acute inflammatory lesions typical of serum sickness
developed in the heart, blood vessels and kidneys. Any antigen
injected after the formation of a permanent antibody excess was
incorporated immediately into insoluble antigen-antibody aggregates
and quickly removed from the circulation. Secondly there may be no
antibody response in which case the animal has a considerable amount
of antigen in the circulation at all times with no evidence of disease
Thirdly those animals making antibody responses too small to cause
elimination of antigen but sufficient to be incorporated into
circulating complexes were found to develop chronic progressive
glomerulonephritis. The disease could be turned off or on by
changing the dose of antigen. If the dose was increased to allow a
continual antibody excess, the disease did not progress. If the dose
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was again changed to a level giving rise to soluble complexes, the
disease would progress. Membranous glomerulonephritis was the most
common disease and as it progressed, proliferative and scarring reactions
developed. Electron microscopy showed a lumpy, dense deposit along
the outer aspect of the basement membranes corresponding to the antigen,
gammaglobulin, and complement-rich deposits visualized with the
fluorescent antibody technique.
Dixon concluded from these experiments that the nature of the
disease produced by antigen-antibody interaction depends to a large
extent upon the quantitative relationship of the two reactants and little,
if at all, upon the absolute amount of antibody or upon the immunological
characteristics of the antigen. Where little antibody is produced,
for example in response to prolonged exposure to small amounts of
endogenous or exogenous antigen, the formation of antigen-antibody
complexes in antigen excess could contribute to maintenance of chronic
disease. The site of localization of complexes and subsequent injury
was determined by the physical character and quantity of complexes,
by local anatomical and physiological factors in the tissue, but not
by any immunological relationship between complex and tissue. Chronic
diseases might result from the prolonged presence of circulating
antigen-antibody complexes.
The existence of subclinical levels of complexes in the circulation
may act in other situations as adjuncts to other pathogenic mechanisms.
Dixon (1962) showed that in animals receiving small clinically
ineffective doses of heterologous anti-kidney serum and also injected
intravenously with heat aggregated human gammaglobulin or rheumatoid
serum in non-pathogenic doses, both anti-kidney antibodies and complexes
were localized in the glomeruli and severe glomerulonephritis resulted.
11
Anti-tissue antibodies or specific toxins of little pathogenic
significance and antigen-antibody complexes may participate in the "
development of disease.
From these experimental observations it has been suggested that
complexes alone could not account for all the various pathological
features found in a clinical disease. The determination of the
existence of and the identification of the pathogenic contribution of
immune complexes and the manner in which they are formed might be of
great importance. Factors responsible for the focussing of complexes
upon specific sites might be present in particular situations and
could be responsible for the development of disease in some individuals
but not in others.
The mechanism governing the deposition of immune complexes in
different tissues has been studied by many workers. Benacerraf and
co-workers (1959) and McClusky and Benacerraf (1959) reported from
their experiments with mice that antigen-antibody complexes, by
releasing substances such as histamine, produce changes in the
endothelium of glomeruli and blood vessels which lead to the arrest of
complexes at these sites and in turn to tissue damage. Cochrane
(1963a, b) showed in guinea-pigs that immune complexes could be made
to deposit in the walls of venules by simultaneous infusion of agents
that increased vascular permeability. Using particles visible with
electron microscopy, Cochrane (1963a) showed that antigen-antibody
complexes were localized by being trapped in the vessel wall along the
basement membranes. In further experiments, Cochrane and Hawkins
(1968) found that only large (greater than 19S) immune complexes became
entrapped in vessel walls. Kniker and Cochrane (1968) and Cochrane
(1971) demonstrated the presence of an active mechanism whereby
immune complexes increase vascular permeability. The administration
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of antagonists of vasoactive amines during the time that immune
complexes appear in the circulation was found to prevent the deposition
of immune complexes in arteries and glomeruli. In addition, when
platelets were depleted in rabbits with serum sickness there was a
marked suppression of deposition of immune complexes and the subsequent
development of arterial and glomerular lesions.
1.2. METHODS USED FOR THE DETECTION OF IMMUNE COMPLEXES
Early attempts to detect immune complexes involved the
demonstration of gammaglobulin deposited in tissue lesions associated
with various pathological conditions. Utilizing the fluorescent
antibody technique, Vazguez and Dixon (1956, 1957) demonstrated the
presence of gammaglobulin in amyloid deposits in secondary human
amyloidosis and in experimental amyloidosis in rabbits, and in lesions
of rheumatic fever, rheumatoid arthritis and systemic lupus
erythematosis (SLE).
Mellors and Ortega (1956) found gammaglobulin localized in the
site of the glomerular lesions in chronic membranous glomerulonephritis
and in other types of glomerulonephritis, as well as in the glomerular
and arterial lesions of periarteritis nodosa. Similarly Mellors and
co-workers (1957) demonstrated the presence of gammaglobulin in
glomerular lesions of renal amyloidosis and lupus erythematosus.
IgG and the 03 component of complement were detected by the
immunofluorescent technique in granular intra- and extra-cellular
deposits in synovial tissue from patients with rheumatoid arthritis
(Fish et al., 1966). Similar results were reported by Brandt and
co-workers (1968) in synovial tissue from patients with rheumatoid
arthritis, SLE and Reiter's syndorome. Kinsella and co-workers (1969)
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detected IgG and C3 in the cytoplasm of most of the phagocytic lining
cells of synovia obtained from both sero-negative and sero-positive
patients with rheumatoid arthritis. Electron microscopy studies have
been used to demonstrate the morphological changes associated with
immune complexes. Electron-dense deposits along the outer aspect of
the basement membrane of affected glomeruli were detected in kidneys
from patients with acute, subacute and chronic glomerulonephritis, and
in lupus nephritis (Dixon, 1962).
More direct methods for detecting immune complexes are those
demonstrating soluble complexes within the circulation. These methods
depend on the biological activity or/and the physical characteristics
of the complexes.
Some of those methods which depend on the biological activity of
complexes rely on the ability of complexes to fix complement components.
The Clq component of complement contains the site through which the
first component combines with gammaglobulin (Muller-Eberhard and
Calcott, 1966; Muller-Eberhard, 1968). Muller-Eberhard and Kunkel
(1961) demonstrated that Clq can be precipitated by soluble gammaglobulin
aggregates. Agnello and co-workers suggested the use of Clq to
demonstrate immune complexes by precipitation in gel. They used this
method to detect gammaglobulin complexes in sera or synovial fluid from
patients with various types of connective tissue disease such as SLE
and rheumatoid arthritis. Sera from patients with chronic glomerulo¬
nephritis and other miscellaneous hypocomplementaemic diseases were
also screened by this method (Agnello et_al., 1969, 1970, 1971).
Mowbray and co-workers (1973) developed the anti-complementary
method for the detection of soluble complexes. This technique was
based on the ability of complexes to bind to the C1 component of
guinea-pig complement after the destruction of C1 already bound to the
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complexes by heat inactivation of the serum. In the presence of
complexes, lysis of added sensitized sheep erythrocytes was inhibited.
This method was used to detect complexes in sera of patients with
dermatitis herpetiformis. The same method was used by Calder and
co-workers (1974) to detect complexes in sera of patients with thyroid
disorders. Johnson and co-workers (1975) reported the use of this
method to detect complexes in sera from patients with disseminated
lupus erythematosus, angioedema urt^icaria, coeliac disease, cutaneous
vasculitis, glomerulonephritis with and without fibrinoid necrosis and
polyarteritis nodosa.
Creighton and co-workers (1973) demonstrated that antigen-
antibody complexes can be precipitated by different concentrations of
polyethylene glycol (PEG). Radiolabelled Clq was used to detect
complexes after precipitation by PEG (Nydegger et_al., 1974). This
method was applied to the detection of complexes in sera from patients
with SLE and carriers of hepatitis B antigen with or without hepatitis.
This method was modified by Zubler and co-workers who treated the
serum with ethylenediaminetetraacetic acid (EDTA), in order to prevent
the integration of radiolabelled Clq into the intrinsic Clqrs complex,
and applied this modification to the detection of complexes in sera of
patients with SLE (Zubler et_al., 1976a). Sera and synovial fluid
from patients with rheumatoid arthritis were screened using this
technique (Zubler et al., 1976b). Sobel and co-workers (1975) developed
another method based on the binding of Clq to immune complexes.
Radiolabelled Clq was added to serum and sensitized sheep erythrocytes
were used to detect unbound Clq. The serum was heat-inactivated in
order to free the complexes from bound C1q before addition of the
radiolabelled Clq. This assay, the Clq deviation test, was used to
detect complexes in sera from patients with Dengue haemorrhagic fever.
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Svehag (1975) described a solid-phase radioimmunoassay for Clq-
binding immune complexes. This method was based on the absorption of
Clq to a fixed inner surface area of polystyrene tube and subsequent
incubation with the test serum. After the addition of radiolabelled
aggregated IgG, the tubes were washed and counted. Low activity in
the tubes was taken to indicate the presence of immune complexes in the
test serum. Sera from patients with rheumatoid arthritis, SLE,
vasculitis and chronic hepatitis were examined for complexes by this
method.
A similar solid-phase radioimmunoassay for Clq-binding complexes
has been described by Hay and co-workers (1976). This assay involves
the addition of radiolabelled anti-human IgG antibody, and in this
case increased activity was indicative of increasing amounts of complexes
bound to the C1q on the surface of the tubes. The sera of patients
with SLE were tested by this method. Quantitation of the amount of
complexes was also reported.
Other assays based on the ability of complexes to bind to
different cell receptors - Fc receptors on cytotoxic lymphocytes,
macrophages and platelets - have been used to detect immune complexes.
Jewell and MacLennan (1973) described a method based on the inhibition
of antibody-dependent cell-mediated cytotoxicity, by competition
between the soluble complexes under investigation and the antibody-
coated target cell for the Fc receptors on the effector cell. This
method was based on the finding of MacLennan (1972), that lymphocyte
mediated cytotoxicity is susceptible to inhibition by third party
immune complexes which compete with target cell bound antibody for
immunoglobulin receptors on the cytotoxic lymphocytes. Using rat
51
spleen lymphocytes as effector cells and Cr labelled Chang liver
cells as target cells, complexes could be detected by counting the
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activity released by effector cells previously incubated with serum
containing complexes. Complexes were detected in inflammatory
bowel diseases (Crohn's disease and ulcerative colitis) using this
method (Jewell and MacLennan, 1973). A modification of this method
was used to detect complexes in sera from patients with bronchogenic
carcinoma and thyroid disorders (Barkas et al., 1976).
Onyewotu and co-workers (1974) reported the use of guinea-pig
peritoneal exudate cells to detect immune complexes. It was based
on the competitive inhibition of the ability of these cells to ingest
soluble immune complexes. Guinea-pig peritoneal macrophages were
treated with human IgG, and heat-inactivated test sera and radiolabelled
aggregates were added simultaneously to the washed cells. In the
presence of complexes in test serum less activity could be detected in
the cells. Sera from patients with SLE were tested by this method.
Mohammed and co-workers (1977) described a modification of this
method. The plastic tubes used for the assay were coated with
guinea-pig serum to reduce the non-specific uptake of radioactivity on
the wall of the tube. This modified method was used to detect complexes
in sera from patients with SLE and rheumatoid arthritis.
Human platelets were found to aggregate in the presence of
soluble immune complexes (Penttinen amd Myllyla, 1968; Penttinen
et al. , 1969). This property has been used by many workers to detect
soluble complexes. The binding of immune complexes to platelets
was found to be through Fc rec-eptors. Sera from patients with fever
of unknown aetiology, hepatitis, rheumatoid arthritis, SLE, leprosy,
mycoplasma pneumonia, sarcoidosis, kidney transplantation and
nitrofurantoin treatment were tested by this method (reviewed by
Penttinen, 1977).
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C3 complement receptors on lymphocytes derived from adenoid
tissue were used by Ezer and Hayward (1974) for the detection of
soluble immune complexes. The method was based on the inhibition
of complement-dependent rosette formation by complexes. Washed
lymphocytes were incubated with test sera and then with erythrocytes
coated with antibody and complement. In the presence of complexes
rosette formation was inhibited. Sera from patients with Crohn's
disease, leprosy and membranous glomerulonephritis were tested by this
method.
Theofilopoulos and co-workers (1976) developed a radioimmunoassay
based on the binding of complexes to complement receptors on a human
lymphoblastoid cell line (Raji cells). The amount of complexes bound
to the cells was determined by estimating the amount of radiolabelled
anti-human IgG bound to the complexes and referring to a standard
curve of radiolabelled uptake by cells previously incubated with
various amounts of aggregated human IgG. This method was used to
detect and quantitate complexes in sera from patients with SLE,
malignancies, serum hepatitis, various types of vasculitis and
subacute sclerosing panencephalitis.
The ability of bovine conglutinin to bind fixed complement was
used to detect immune complexes through binding to C3 fixed to
complexes (Eisenberg et al., 1977). A solid state radioimmunoassay
was used in which the conglutinin was adsorbed to plastic tubes.
Sera from patients with SLE, subacute bacterial endocarditis, vasculitis,
glomerulonephritis, multiple sclerosis and cancer were tested for
complexes by this method. A similar method was used by Casali and
co-workers (1977) to detect complexes in the sera of patients with SLE,
vasculitis, leprosy and leukaemia.
The ability of rheumatoid factor to react with IgG containing
complexes has been used by many workers to detect immune complexes.
Kunkel (1961) described the inhibition by certain human sera of the
capacity of rheumatoid factor to agglutinate erythrocytes coated with
antibodies. Inhibition of agglutination of IgG-coated polystyrene
particles (latex) was applied for the detection of IgG complexes in
eluates from rheumatoid tissue (Munthe and Natvig, 1971). IgM
rheumatoid factor was mixed with the test sample and then with the
latex reagent, and in the presence of complexes no agglutination could
be detected. Cowdery and co-workers (1975) described a radioimmunoassay
which measured the competitive binding of immune complexes to rheumatoid
factor. It was based on the inhibitory activity of immune complexes
in the test sera on the binding of rheumatoid factor to radiolabelled
aggregated IgG. Sera from patients with SLE, rheumatoid arthritis,
polymyositis, hepatitis, melanoma and lymphocytic leukaemia were
tested for complexes by this method. Inhibition of agglutination of
IgG-coated particles by rheumatoid factor and Clq was used by Lurhuma
and co-workers (1976) to detect complexes in sera from patients with
Crohn's disease, liver disease, idiopathic thrombocytopenia,
glomerulonephritis, rheumatoid arthritis, mylomatosis, different types
of leukaemia, lymphosarcoma, SLE, ankylosing spondylitis, scleroderma,
autoimmune haemolytic anaemia and chronic urticaria. Cambiaso and
co-workers (1977) have described the use of an automated version of .
this method, while Levinsky and Soothill (1977) have reported the use
of low affinity IgM antibodies to human immunoglobulins instead of
rheumatoid factor.
Radiolabelled goat anti-human IgG monovalent (Fab) antibody
fragments were used to detect immune complexes by Ludwig and Cusumano
(1974). The method was based on the incubation of test sera with the
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radiolabelled monovalent antibody and the subsequent appearance of
a radiopeak after sucrose gradient velocity sedimentation. This
method was used to detect complexes in patients with cancer or collagen
disease.
Indirect markers of circulating immune complexes have been used
to show the presence of complexes. C3 bound to complexes was detected
after separation from free C3 by chromotography (Williams and Slaney,
1977). The test sera were fractionated on Sephadex G-200 and the
eluted factions were tested for the presence of C3. Free C3 usually
appeared in the second peak, while C3 bound to immune complexes appear
in the first peak.
1.3. IMMUNE COMPLEXES MP THYROID DISORDERS
The possible role of humoral antibodies and cell mediated
hypersensitivity in the pathogenesis of thyroid disease has received
much attention.
In the late 1950s and early 1960s interest in the immunological
aspects of thyroid disease was centred around the identification and
possible pathogenic significance of thyroid-specific autoantibodies
present in the serum of patients with autoimmune thyroid disease.
Evidence for and against the direct mediation of tissue damage by
circulating antibodies has been obtained from a number of studies
involving both passive and active immunization. High-titred antiserum
from autoimmunized rats or rabbits has been injected repeatedly into
normal recipients without evoking any specific lesions in their thyroid
glands (Anigstein, 1957; Rose et al., 1962). Nakamura and Weigle
(1969) reported that thyroid lesions developed in rabbits receiving
pooled sera from thyroidectomized donors, but only if the serum was
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taken within 1 5 days after thyroidectomy. Immunofluorescent studies
of recipient thyroid glands showed focal fixation of rabbit IgG and C3
complement components in the thyroid follicles. There were no thyroid
lesions in recipient animals injected with late antiserum or with
antiserum from non-thyroidectomized donors.
Other workers have reported the successful passive transfer of
thyroiditis using antisera prepared in foreign species (Lilien, 1954).
Sharp and co-workers (1967) injected guinea-pigs with antiserum prepared
by immunizing rabbits with guinea-pig thyroglobulin and observed intense
eosinophilic infiltration in the interstitial areas of the gland.
They presumed that the formation of thyroglobulin-antibody complexes
attracted the eosiniphils. The lesion was resolved in 2 to A weeks
without evidence of typical lymphocytic thyroiditla On the other hand,
Roitt and Doniach (1958) demonstrated that the transfusion of large
quantities of Hashimoto serum to Rhesus monkeys produced no changes in
the thyroid gland. These observations, together with the fact that
thyroiditis is rarely observed in babies of affected mothers although
anti-thyroglobulin antibodies in high titre can cross the placenta
(Parker and Beierwaters, 1961), have shown that antibody cannot be
solely responsible for lesions observed in the thyroid gland.
The role of cell mediated immunity in the pathogenesis of thyroid
disease has been studied by many workers using the leucocyte migration
inhibition test. Soberg and Hallberg (1968) first demonstrated that
the migration of leucocytes from 80 per cent of patients with Hashimoto
thyroiditis was significantly inhibited when an homogenate of human
thyroid gland was added to the culture medium. Subsequently others
have reported similar findings using not only thyroid gland homogenate
but also thyroglobulin and microsomal antigens (Brostoff, 1970; Calder
et_al., 1972; Lamki et_al., 1973; Wartenberg et_al., 1973a, b). The
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inhibitory effect of thyroid antigens on the migration of leucocytes
from patients with Hashimoto thyroiditis or thyrotoxicosis was suggested
to be due to the release of migration inhibition factor from T
lymphocytes specifically sensitized to thyroid autoantigens, although
this phenomenon could also be independent or only partially dependent
upon the presence of autoreactive T cells (Calder and Irvine, 1975).
The antigen-induced transformation of small lymphocytes to large
"blast like" forms has also been used as an indication of cellular
hypersensitivity, with conflicting results. Although some workers
were able to demonstrate the transformation of lymphocytes from patients
with thyroiditis in response to thyroglobulin (Ehrenfeld et_al., 1971;
Delespesse et al., 1972), others have been unsuccessful (Groot and
Jaksina, 1969; Calder and Irvine, 1975).
Evidence that immune complexes may be involved in autoimmune
thyroid disorders has been presented in the last few years. Werner and
co-workers (1972), using immunofluorescent techniques, demonstrated the
presence of human IgG, IgM, IgE and complement components C1q and C3
in focal areas of the stroma as well as in the follicular basement
membrane of thyroid glands from patients with Graves' disease.
Kalderson and co-workers (1973) demonstrated the presence of distinct
electron-dense deposits in the follicular basement membrane of some
follicles in the thyroid gland of eight patients with Hashimoto
thyroiditis which closely resembled the antigen-antibody deposits of
immune complexes nephropathies. Podleski (1972) reported the cytotoxic
effect of lymphocytes from patients with Hashimoto thyroiditis on
target cells coated with either thyroglobulin or the microsomal fraction
of human thyrotoxic gland. Calder and co-workers (1973b) obtained
similar results using lymphocytes from patients with Hashimoto thyroiditis
and thyroglobulin-coated chicken red blood cells.
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Normal human lymphocytes were found to be cytotoxic to
thyroglobulin-coated chicken red blood cells which had been pre-
incubated with decomplemented sera (Calder et al., 1973a, 1975)- The
cytotoxic activity was found to correlate with the titre of thyroglobulin
tanned cell haemagglutinating antibody. Wasserman and co-workers (1974)
reported similar findings, but found no correlation between cytotoxic v
activity and antibody titre. The cytotoxic factor in Hashimoto serum
was found to be an antibody of the IgG class, detectable in both the
19S and 7S G-200 Sephadex fractions of serum (Calder et al., 1973c).
It was suggested that the cytotoxic activity associated with higher
molecular weight was due to the presence of antigen-antibody complexes,
and that these complexes in antibody excess might be responsible for the
arming of killer cells, giving them the specificity to destroy
appropriate antigen-labelled target cells. Lymphoid cells from normal
donors were incubated with Hashimoto serum known to contain 19S-
localized cytotoxic activity and then washed thoroughly. These cells
were able to destroy target cells coated with thyroglobulin, but not
uncoated target cells (Calder et al., 1973a).
Circulating soluble immune complexes were demonstrated using the
anti-complementary method in the sera of patients with thyroid disorders
(Calder et al., 1974; Calder and Irvine, 1975)- Anti-complementary
activity was found to be in a higher precentage of sera from patients
with Hashimoto thyroiditis than those from patients with primary
hypothyroidism or thyrotoxicosis. This activity of serum samples
from patients with Hashimoto thyroiditis was localized predominantly
in the ascending peak of the IgG distribution profile. It was suggested
that this localization was due to the presence of immune complexes and
that the antigen involved might be thyroglobulin or thyroid microsomal
antigen.
In the present study the detection and quantitation of soluble
immune complexes in the sera of patients with thyroid disorders was
carried out. The correlation between the presence and quantity of
complexes and the clinical features of the patients was also studied.
1.4. IMMUNE COMPLEXES AND DIABETES MELLITUS
Considerable interest has lately been shown in the possibility
that immunological processes may have an aetiological role in the
pathogenesis of diabetes mellitus, and in particular the insulin
dependent type which is often associated clinically and serologically
with autoimmune diseases of the thyroid, the gastric mucosa and the
adrenal cortex (Irvine et_al., 1970; Nerup and Binder, 1973).
Pancreatic islet-cell antibodies were first described in the
sera of patients with polyendocrine disease associated with insulin-
treated diabetes (Bottazzo et al., 1974; MacCuish et al., 1974a).
Subsequently, Lendrum and .co-workers (1975) reported the presence of
antibodies in newly diagnosed diabetics. These antibodies were found
to be more frequently detected in newly diagnosed insulin dependent
diabetics than in those studies one year after diagnosis (Lendrum
et al., 1976; Irvine et al., 1977). Cell mediated hypersensitivity
to pancreatic antigens has been demonstrated predominantly in patients
with juvenile diabetes of short duration (Nerup et al., 1971, 1974;
MacCuish et al.. 1974b; Richens et al., 1976). Lymphocytic
infiltration in and around the islets of Langerhans is characterisitic
of this type of diabetes (Warren, 1927; LeCompte, 1958; Gepts, 1965).
The possible pathogenic significance of insulin-anti-insulin
antibody complexes has been indicated by the observations of a number
of investigators. The presence of anti-insulin antibody in sera of
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diabetics was detected as early as 1944 when Lowell reported the
presence of insulin neutralizing factor in sera of insulin-dependent
resistant diabetics. Subsequently, Berson and co-workers (1956)
demonstrated the presence of "insulin-transporting globulin" complexed
with insulin in the blood of insulin treated subjects. The presence
of anti-insulin antibodies has been confirmed by other investigators
(Kalant et al., 1958; Skom and Talmage, 1958; Pav et al., 1963;
Ortved Andersen, 1972). Quantitative studies of the interaction
between insulin and insulin binding antibodies showed the existence of
high and low affinity insulin antibodies in sera of insulin treated
subjects (Berson and Yallow, 1959).
Freedman and co-workers (1960) using a fluorescence technique
were able to demonstrate gammaglobulin in nodules of diabetic
glomerulosclerosis. Similarly Blumenthal and co-workers (1964)
demonstrated the presence of insulin and complement in the affected
glomerular tissue in diabetics.
Diabetes has been produced in animals by the infusion of serum
obtained from guinea-pigs immunized with insulin (Wright, 1961).
Grieble (1960), Blumenthal (1964) and Ditscherlein and co-workers (1967)
induced glomerulosclerosis in rabbits immunized with insulin. Similar
findings were reported by Zampa and Mancini (1965) and Andreev and
co-workers (1970) in guinea-pigs after immunisation with insulin.
The binding of radiolabelled insulin to vessels from subcutaneous
and muscular tissues of insulin-treated diabetics has been reported
(Poulsen and Werner, 1969). Werner and Larsen (1969) demonstrated the
binding of fluorescein-conjugated insulin and IgG from diabetics to
ocular structures from insulin-treated diabetics. Osterby (1972)
demonstrated by electron-microscopy a thickening of the glomerular
basement membrane 2-3 years after the beginning of insulin treatment.
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Ortved Andersen (1976) reported that patients with diabetic
complications, especially those with early onset of proliferative
retinopathy or nephropathy, had a slightly elevated plasma insulin-
binding capacity and suggested that insulin-anti-insulin antibody
complexes may aggravate the vascular complications.
Soluble antigen-antibody complexes were detected only indirectly
in sera from patients with insulin-resistant juvenile diabetes (Faulk
et al., 1970), and in insulin treated diabetics (Jayarao et al., 1973)
by measuring insulin antibody before and after acid dissociation and
removal of insulin by charcoal-adsorption. The increase in antibody
titre after dissociation was considered to reflect the presence of
immune complexes.
Foiling (1976) demonstrated the existence of different types of
insulin-anti-insulin complexes with different biological properties.
It was suggested that complexes which adhere to vascular walls bind
and activate complement and thereby elicit inflammation.
In the present study detection and quantitation of soluble immune
complexes in sera of patients with different types of diabetes was
carried out. The correlation between the presence and quantity of
complexes and the presence of different types of antibodies and
complications was also studied.
1.5. AIM OF INVESTIGATION
The aims of this study were to investigate the possible presence
of immune complexes in sera of patients with thyroid diseases or
diabetes mellitus, to correlate the presence of immune complexes with
the severity of disease and with the occurrence of serum autoantibodies,
and to define the role of immune complexes in the development of these
diseases.
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In addition, attempts were made to characterize the detected
complexes in terms of their antigen components and to develop a
more sensitive assay for the detection of immune complexes.
1.6. METHODS USED IN THIS STUDY
When the present study was initiated there was a limited number
of relatively insensitive methods available for the detection of
circulating immune complexes in human sera. Of these, the most
useful appeared to be the ADCC inhibition assay of Jewell and MacLennan
(1973) which was based on the competitive binding of immune complexes
and antibody-coated target cells (Chang liver cells) to the Fc
receptors on effector cells (human peripheral blood lymphocytes).
In this laboratory, experiments were being carried out to modify
and improve the sensitivity of this assay by using chicken red blood
cells as target cells and human peripheral blood lymphocytes as
effector cells. However, difficulties were encountered with this
modification due to the variability of the peripheral blood lymphocytes
obtained from different donors, and the technique was again modified
by using chicken red blood cells as targets and rat spleen lymphocytes
as effector cells. This assay was found to be sensitive and
reproducible and was used in the first part of this study.
During the progress of the present study, two new methods
appeared in the literature. In 1975, Sobel and co-workers described
a C1q deviation test which was based on the competition between immune
complexes and antibody-coated sheep erythrocytes for the binding of
radiolabelled Clq. In the following year, Theofilopolous and co-workers
described the Raji cell radioimmunoassay. This was based on the
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binding of immune complexes to the complement receptors on human
lymphoblastoid cells and the subsequent detection of these complexes
by radiolabelled anti-IgG antibodies.
Both methods were reported to be more sensitive than the ADCC
inhibition assay and experiments were carried out to apply these
techniques in this study. The Raji cell radioimmunoassay differed
from the ADCC inhibition and Clq deviation assays in that heat-
inactivation of serum was not required, thus eliminating the
possibility of aggregate formation. In addition, it also permitted
the quantitation of complexes present in the sera under test. A
modification of the assay was used in attempts to characterize the
immune complexes detected in sera of patients with thyroid disease and
to eliminate the possible influence on the sensitivity of the assay of
monomeric IgG present in serum samples with high levels of IgG.
Finally, a novel sensitive and reproducible assay was developed
using the binding of immune complexes to the Fc receptors on rat
spleen leucocytes and the subsequent detection of these complexes by
the addition of radiolabelled anti-IgG antibody. Immune complexes
were also quantitated by this method.
MATERIALS AND METHODS
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2.1. INHIBITION OF ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY (ADCC)
2.1.1. Reagents
Eagle's medium (1x strength, without glutamine) with added
antibiotics (1000p/ml penicillin and 500ng/ml streptomycin) was used as
a basic diluent throughout this work. For the assay procedure, this
medium was further supplemented with 10% foetal calf serum (FCS) and
2mM glutamine. The FCS was heated in a water bath at 56°C for 30 min
before use in order to inactivate the complement.
2.1.2. Preparation of effector cells
Preliminary studies in this laboratory have shown that in
different inbred strains of rat there may be considerable variation in
the antibody-dependent cell-mediated cytotoxicity exerted by spleen
cells. One of the strains, namely Liverpool Hooded (Ag-B Genotype),
whose spleen cells were among the more effective, was chosen for this
work. The animals were obtained from a colony maintained within the
animal house of the Unit of Reproductive Biology, Forrest Road,
Edinburgh.
9-15 week-old male rats were killed by asphyxiation in a carbon
dioxide atmosphere. The spleens were removed and gently hand-
homogenized in a few ml of Eagle's medium using a glass homogenizer.
The cell suspension was decanted and centrifuged at AOOg for 5 min.
The cells were resuspended in 10ml Eagle's medium + supplements, and
incubated at 37°C for two hours in a flat-sided glass bottle to allow
adherence of mononuclear phagocytes. The non-adherent cells were
then removed, centrifuged and resuspended in 20ml Eagle's medium plus
supplements. The leucocytes were counted, and the suspension
diluted to the required concentration.
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The viability of the cells was assessed by staining with Trypan
Blue. Equal volumes of cells in Eagle's medium (I0x10^/ml) and 1%
Trypan Blue in phosphate buffered saline (PBS, 0.1M pH7.2) (Appendix
II) were mixed for 5 min. at room temperature. Cell viability,
estimated using a haemocytometer, was generally 90-95%.
2.1.3. Preparation of target cells
Blood was obtained from the wing vein of White Leghorn chickens
aged between 6 to 12 weeks. 2 to 5ml were collected on the day of use
into a tube containing sufficient heparin to give a final concentration
of 10u/ml. The suspension was centrifuged at 200g for 10 minutes, the
plasma and buffy coat discarded, and the cells washed twice in Eagle's
medium and once in PBS.
50pl of an 8% suspension of the chicken red blood cells (CRBC)
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in Eagle's medium were incubated with 20pl (200pCi) Cr-labelled sodium
chromate at 37°C for 2 hours. The radiolabelled cells were then
washed three times with Eagle's medium, made up to 2ml in Eagle's
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medium plus supplements, counted, and diluted to 2x10 /ml.
2.1.A. Preparation of antiserum to CRBC
Antisera were raised in rabbits by a course of two intramuscular
injections separated by an interval of 10 days. Each injection
consisted of 1ml 10% suspension of CRBC in PBS emulsified with an equal
volume of Freund's complete adjuvant. The rabbits were boosted with a
further injection of CRBC in adjuvant 5 months later. They were bled
from the ear vein 10 days after the second injection and again 10 days
after the booster injection and the sera were stored in 100pl aliquots
at -20°C. All sera were heat inactivated at 56°C for 30 minutes prior
to use and then tested for potency in the antibody-dependent cell-
mediated cytotoxicity assay.
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2.1.5. Preparation of aggregated human IgG and formed antigen-antibody
complexes
The sensitivity of the ADCC inhibition assay for the detection
of complexes was investigated using aggregated human IgG and formed
antigen-antibody complexes.
2.1.5.1. Aggregated human IgG
As a source of human IgG, normal human immunoglobulin was
obtained from the Blood Transfusion Service, Edinburgh. This material
was prepared for therapeutic use by ethanol fractionation. Its stated
purity was 93% IgG. No further tests on its purity were carried out.
The concentration was adjusted to AGmg/ml in PBS, and the solution
heated at 63°C for 15 minutes. The suspension of aggregated IgG was
used without further treatment.
2.1.5.2. Ovalbumin-antiovalbumin complexes
Varying concentrations of ovalbumin were added to neat
antiovalbumin antiserum in a microprecipitation test in order to find
the optimal concentration for the formation of precipitates. After
precipitation the supernatants were tested for the presence of free
antigens and antibody using Ouchterlony immunodiffusion. The optimal
concentration of ovalbumin for the formation of a precipitate with neat
antiserum was found to be 312pg/ml.
The precipitate was suspended in 0.2ml PBS; this initial
concentration of formed complexes as determined by spectrophotometery
was 600pg/ml. The suspension was further diluted to 60pg/ml using
1/10 heat inactivated normal human serum in Eagle's medium. Subsequent
dilutions were made using Eagle's medium only.
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2.1.6. Serum samples
Serum samples were obtained from patients with thyroid disorders
attending the Endocrine Unit, Royal Infirmary of Edinburgh (RIE) for
diagnostic investigation before treatment, or for follow-up within 5
years of diagnosis. The patients were selected after clinical
examination and according to certain criteria after investigations
carried out by the Endocrine Unit (radio-iodine uptake, anti-thyroid
antibody titres), the clinical chemistry laboratory, RIE (total plasma
thyroxine and triiodothyronine, effective thyroxin ratio, protein bound
iodine (PBl)) and the Regional Hormone Laboratory, Forrest Road,
Edinburgh (thyroid stimulating hormone (TSH) measurement with or
without thyroid releasing hormone (TRH) stimulation as appropriate).
2.1.6.1. Hashimoto thyroiditis
Twenty-five female goiterous patients (Age 42-71, mean 56.5)
were studied. Of these, one was newly diagnosed and the remainder had
been diagnosed up to 10 years previously (mean 32.4 months). Nineteen
had significant titres of thyroid antibodies (tanned red cell
haemagglutination (TCH) titre > 1:2500 and/or a complement fixation
(CFT) titre > 1:32). Three were confirmed histologically by needle
or open biopsy, while the remaining three patients were diagnosed on
the concurrence of goitre, hypothyroidism and low titres of anti-thyroid
antibodies.
One patient was hypothyroid and another was mildly hypothyroid
at the time of the study, while the remainder were euthyroid. All the
patients except three were taking thyroxine for either hypothyroidism
or impaired thyroid reserve or to reduce the goitre size.
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2.1.6.2. Primary hypothyroidism
Twenty-nine patients (F22, M7, Age 15-83, mean 60.9) were
studied. Of these, 10 were newly diagnosed and the remainder had been
diagnosed up to 5 years previously (mean 19.7 months). Initially all
were clinically and on investigation unequivocally hypothyroid (low
level of total serum thyroxin or PBI and elevated level of TSH or no
response to exogenous TSH stimulation), with no palpable goitres. All
except the newly diagnosed patients were on thyroxine at the time of the
study and were euthyroid apart from one who remained hypothyroid 6 months
after treatment.
2.1.6.3. Thyrotoxicosis
Twenty-six patients (F23, M3, Age 1 -4—66, mean 37) who were
clinically and on investigation unequivocally thyrotoxic (elevated total
serum thyroxine and/or triiodothyronine and suppressed TRH response)
were studied prior to any definitive treatment. Four of these were on
propranolol. Two had previously been treated with carbimazole and had
subsequently relapsed, but none had undergone surgery or radio-iodine
treatment. Goitres were palpable in all patients with none showing
evidence of nodularity clinically or on scanning.
2.1.6.A. Treated thyrotoxicosis
Twenty-six patients (F19, M7, Age AO-81, mean 52.7) had been
131
treated with -4—15 mCi I for unequivocal thyrotoxicosis at least one
year before study. Of these, two had required a second treatment.
None were thyrotoxic at the time of sampling. One was hypothyroid and
two were mildly hypothyroid and were on thyroxine treatment. The rest
were euthyroid and on no treatment.
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2.1.6.5. Controls
Serum samples from age- and sex-matched controls were obtained
for each patient on the day of sampling. The controls were unrelated
friends of patients, hospital employees, voluntary workers and hospital
patients with illness not considered to be associated with circulating
immune complexes. None had a history of thyroid or other autoimmune
disease.
The sera were stored in 250pl aliquots at -20°C.
2.1.7. Serology
2.1.7.1. Autoantibodies
All sera were routinely tested in the Endocrine Unit for anti¬
thyroid antibodies by indirect immunofluorescence, using rabbit anti-
human immunoglobulin conjugated with fluorescein isothiocyanate and
frozen sections of human thyroid gland, and for anti-thyroglobulin
antibodies by the tanned red cell agglutination test (TCH), using
purified thyroglobulin. All sera found positive for anti-thyroid
antibodies were also tested for the presence of anti-microsomal
antibodies by the complement fixation test (CFT), using thyroid
extract. In addition, all sera were examined for the presence of
anti-gastric parietal cell antibodies by indirect immunofluorescence,
using frozen sections of rat stomach.
2.1.7.2. Estimation of serum IgG levels
Serum concentrations of IgG were determined in all thyroid
patients and controls using commercial radial immunodiffusion plates.
The tested sera and the known control serum were diluted 1 in 5 with
physiological saline. For each plate the well positions of the three
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reference sera, the known control serum and each test sample were
recorded. 5pl of each sample was applied to the appropriate well
using a disposable glass capillary tube. The plates were left
undisturbed at room temperature but covered until the serum had
diffused into the gel, and then incubated upside down at room
temperature for 20 hours. The diameter of precipitate formed around
each well was measured using a scale rule.
Data for the three reference sera were plotted on semilog graph
paper against concentration of IgG in mg/l00ml and the test sera and
the known control serum were quantitated by relating the ring diameter
measurements to IgG concentration on the curve constructed from the
reference sera data. 1/10 instead of 1/5 dilution was used for sera
giving diameters greater than the highest reference sample.
2.1.8. Fractionation of serum samples
Eight serum samples (3 Hashimoto, 1 hypothyroid and their matched
controls) were fractionated on Sephadex G-200.
2.1.8.1. Preparation of the gel
30gm of Sephadex G-200 was added to 400ml PBS, and the gel slurry
maintained in a boiling water bath for 5 hours. The gel was deaerated
by water vacuum and poured into a 2.5x82cm column, and the gel bed was
packed by passing buffer through the column.
2.1.8.2. Sample preparation and application
Serum samples were dialysed against two .changes of PBS at 4°C.
2ml of dialysed serum was applied to the top of the gel. When the
sample had entered the gel, buffer was pumped through the column at a
flow rate of 20ml/hour using a peristaltic pump. The eluate was
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collected in 10ml volumes using an Ultrarac fraction collector. The
optical density of the column effluent was estimated using a Uvicord
spectrophotometer reading at 254nm:in order to locate the protein
peaks.
2.1.9. Assay procedure
The ADCC inhibition assay used was a modification of that of
MacLennan (1972). Incubations were set up in triplicate in LP3 tubes
and the mean of the results taken.
Effector cells were adjusted to 10x10^/ml in supplemented
Eagle's medium, giving an effector to target cell ratio of 50:1. 200pl
of each serum sample were heat inactivated for 30 minutes at 56°C, and
medium added to make 1/10, 1/20, 1/40 and 1/80 dilutions. For each
dilution of serum tested, two sets of tubes containing 200pl of the
spleen cell suspension and 100pl of diluted serum were set up. In
addition, two sets of tubes containing 200pl of the spleen cell
suspension and 100pl of medium were prepared. All tubes were incubated
at 37°C for 2 hours in an air-5$ COg atmosphere.
At the end of this period, 20pl of radiolabelled CRBC were
added to each tube. 100pl of appropriately diluted anti-CRBC
antiserum were then added to one set of tubes, while the remaining
tubes received lOOpl of medium, and all tubes were incubated at 37°C
for 16 hours in an air-5% CO^ atmosphere.
The tubes were then centrifuged at 200g for 10 minutes. 200pl
of supernatant were removed and the radioactivity estimated using a
well-type automatic gamma-counter. Total activity was estimated by
counting aliquots of labelled cells. In a few cases where release in
the presence of serum and absence of antibody exceeded that in the
absence of serum and absence of antibody, indicating natural anti-CRBC
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antibodies, the sample and control sera were absorbed with an equal
volume of packed CRBC for 1 hour at 4°C, and reassayed.
The percentage inhibition was expressed according to the
following calculations:
release by effector cells x 2
i) % release = X 100
total activity
(% release in absence of serum sample) -
(% release in presence of serum sample)
ii) % inhibition = X 100
% release in absence of serum sample
Release of label in the absence of antibody was less than 5%-
2.2. RADIOIMMUNOASSAYS
2.2.1. Reagents
Eagle's medium (1x strength, without glutamine) with added
antibiotics (1000p/ml penicillin and 500ng/ml streptomycin) was used as
a diluent in all radioimmunoassays. For the maintenance of Raji cell
cultures, this medium was supplemented with 20% heat-inactivated FCS,
AmM glutamine and 10% tryptose phosphate broth.
2.2.2. Preparation of antisera
Goat antiserum to human IgG was obtained commercially. Rabbit
antiserum to human thyroglobulin was prepared by repeated subcutaneous
and intramuscular injections of 1ml of human thyroglobulin (10mg/ml) in
PBS emulsified with an equal volume of Freund's complete adjuvant. The
rabbits were bled 10. days after the second injection and the sera tested
for antithyroglobulin antibodies by Ouchterlony immunodiffusion.
Immunoglobulin containing fractions from both antisera were
prepared by precipitation with 50% saturated ammonium sulphate solution.
The precipitates were dissolved in normal saline, and the solutions
dialysed against several changes of phosphate buffer (pH7, 0.1M).
The protein concentration was adjusted to 1mg/ml using phosphate
buffer.
2.2.3. Fractionation of goat anti-human IgG antiserum on DEAE cellulose
2.2.3.1. Preparation of the column
DE52 cellulose was washed with 0.5M HC1 for 1 hour, several
changes of distilled water, 0.5M NaOH for 1 hour, several changes of
distilled water, and finally several changes of phosphate buffer (0.5M,
pH8). The gel was then equilibrated in phosphate buffer (0.01M, pH8)
and the slurry poured into a 4x30cm column.
2.2.3.2. Preparation of antiserum
2ml of goat anti-human IgG antiserum was dialysed overnight at
A°C against several changes of phosphate buffer (0.01M, pH8). The
dialysed serum was applied to the top of the column which was then
connected to an ionic gradient generator.
2.2.3-3. Ionic gradient separation of IgG
IgG immunoglobulins were separated from other immunoglobulins
and from other serum proteins using an ionic strength gradient. A
simple exponential gradient was prepared (Fahey & Terry, 1973) using
0.5M Na'Cl in phosphate buffer (0.01M, pH8) in the reservoir, and buffer
only in the mixing chamber. The effluent from the mixing chamber was
pumped to the top of the column. Serum and buffer were then passed
through the column at a flow rate of Ami/hour by the action of a
peristaltic pump, and the eluent collected in 2ml volumes using an
Ultrarac fraction collector. The optical density of the column
effluent was estimated using a Uvicord spectrophotometer reading at
254nm.ii order to locate the protein peaks. The anti-human IgG activity
of each fraction was estimated by Ouchterlony immunodiffusion. The
fractions in each protein peak were bulked and then concentrated
using an Amicon model 12 cell and Diaflo ultrafilters UM 20E (10,000-
20,000MW). Each concentrate was then again tested for anti IgG
activity as above. ,
2.2.4. Aggregation of IgG
Purified human IgG was aggregated as described in 2.1.5.1.
2.2.5. Radioiodination of proteins
Iodination of Clq and of the immunoglobulin fractions of goat
anti-human IgG and rabbit anti-human thyroglobulin was carried out
using a modification of the method of McConahy and Dixon (1966).
2.2.5.1. Preparation of column
One gm Sephadex G-50 was added to 40ml of phosphate buffer
(0.1M, pH7), and the gel slurry maintained in a boiling water bath for
3 hours. The gel was poured into a -|x30cm column and the gel bed was
packed by passing buffer through the column. 30ml of 1^ bovine serum
albumin (BSA) in phosphate buffer were allowed to run through the
column in order to reduce non specific binding of iodinated protein to
the gel.
2.2.5-2. Iodination procedure
One mg protein in 1ml phosphate buffer was labelled with
1mCi"'^^I. After adding I00ql of 200pg/ml chloramine T, the solution
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was mixed on a magnetic stirrer for 5 minutes at room temperature. The
reaction was stopped by the addition of 100pl of 200pg/ml sodium
metabisulphite.
The solution was applied to the top of the column by pasteur
pipette, and 1ml fractions were collected by adding more BSA in
phosphate buffer to the top of the column. The fractions containing
the radioactivity were identified using a Scaler-Ratemeter SR3.
Labelled proteins usually appeared in the fifth and sixth fractions.
Free iodine appeared mostly in the ninth and tenth fractions. The
labelled proteins were stored in 200pl aliquots at -20°.
2.2.6. Collection and preparation of serum samples
2.2.6.1. Serum samples from patients with thyroid disorders
Sera from patients with thyroid disorders were collected
according to the criteria used in 2.1.6.
Twenty three female goiterous patients (Age 18-76, mean 55 years)
with Hashimoto thyroiditis were studied. Of these, two were newly
diagnosed and the remainder had been diagnosed up to 15 years previously
(mean 51 months). Thirteen had significant titres of thyroid
antibodies. Eight were confirmed histologically by needle or open
biopsy, while the remaining two were disgnosed on the concurrence of
goitre, hypothyroidism and low titres of anti-thyroid antibodies.
Three patients were clinically hypothyroid at the time of study:
two of these were newly diagnosed and had not yet been started on
treatment while the other had disabling angina and thyroxine was
discontinued. The remaining patients were euthyroid and all except
one were taking thyroxine for either hypothyroidism or impaired thyroid
reserve or to reduce the goitre size.
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Twenty-eight patients (F26, M2, Age 37-78, mean 61.7 years) with
primary hypothyroidism were studied. Of these, 6 were newly diagnosed
and the remainder had been diagnosed up to 8 years previously (mean
41.4 months). Initially all were clinically and on investigation
unequivocally hypothyroid with no palpable goitres. All except the
newly diagnosed patients were on thyroxine at the time of study and were
euthyroid except one who remained hypothyroid 3 months after treatment.
Twenty patients (F16, M4, Age 21-68, mean 40.1 years) who were
clinically and biochemically and on investigation unequivocally thyrotoxic
were studied prior to any definitive treatment. Ten were taking
propranolol at the time of study. Nine had recurrent thyrotoxicosis
after carbimazole treatment 1 to 11 years previously. Goitres were
palpable in 18 patients with none showing evidence of nodularity
clinically or on scanning.
The patients used in this study were not the patients used in
the previous study (ADCC inhibition assay).
2.2.6.2. Serum samples from diabetics
Serum samples were collected from patients attending the diabetic
outpatients department, Royal Infirmary, Edinburgh.
Thirteen newly diagnosed juvenile insulin dependent diabetics
(F4, M9, Age 13-30, mean 20.8 years) were studied. These had not been
treated with insulin or had been receiving insulin for only a short
period (from a few hours to a few days).
Thirty-two patients (F15, M17, Age 16-83, mean 43 years) with
insulin dependent diabetes who had been treated with insulin for
periods ranging from 1 month to 30 years were studied. Thirty-one
diabetics (F21, M10, Age 15-80, mean 59-9 years) treated with oral
hypoglycemic agents (0HA) who were either newly diagnosed or had been
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receiving treatment for periods ranging from a few days to 21 years, and
twenty one diabetics (F11, M10, Age 37-82, mean 60.5 years) receiving
no treatment other than restrictions on diet and who were either newly
diagnosed or had been diagnosed up to 25 years previously were also
studied.
Serum samples were obtained from age- and sex-matched controls as
described in 2.1.6. All sera were stored in 500pl aliquots at -40°C.
2.2.7. Serology
2.2.7.1. Sera from patients with thyroid disorders
All sera obtained from patients with thyroid disorders were
tested as described in 2.1.7.1.
2.2.7.2. Diabetic sera
i. Anti-islet cell antibodies
All sera were tested by the Endocrine Unit, RIE, for anti-islet
cell antibodies by indirect immunofluorescence, using fresh post mortem
snap-frozen pancreatic tissue (blood group 0). Sera that were
positive when tested neat were titrated using doubling dilutions,
ii. Anti-viral antibodies
The sera of the thirteen newly diagnosed insulin-dependent .
diabetics and their age- and sex-matched controls were screened and
titrated for antibodies to Coxsackie viruses B1-5 by a metabolic
inhibition test, to Epstein Barr virus by an indirect immunofluorescence
test, and to Rubella virus using a haemagglutination inhibition test.
Sera were screened and titrated for complement fixing antibody to the
following antigens - Influenza A, B and C, Parainfluenza type 1, Measles,
Mumps S and V, Respiratory Syncytial virus, Adenovirus, Cytomegalovirus,
A3
Varicella zoster, Herpes simplex, Coxiella burneti phase 2, Chlymydia
Group B and Mycoplasma pneumoniae. These tests were all carried out
by the Virology Department, City Hospital, Edinburgh,
iii. Anti-insulin antibodies
Antibodies to insulin were, estimated in all diabetic sera by a
minor modification of the method of Ortved Andersen and colleagues
(1972), according to Mustaffa and co-workers (1977). Insulin binding
of 10pU/ml serum was regarded as indicative of the presence of anti-
insulin antibodies. Insulin binding between 10-300pU/ml serum was
regarded as indicating moderate anti-insulin antibody titre, while
binding of > 300pU/ml was interpreted as binding due to high titres of
anti-insulin antibodies. This investigation was carried out in the
Middlesex Hospital, London.
2.2.8. C1q deviation test (modified from Sobel et al., 1975)
2.2.8.1. Preparation of sensitized sheep erythrocytes (SRBC)
Blood was collected from the jugular vein of a male sheep,
heparinised (Evan's 10u/ml) and centrifuged at 200g for 10 minutes.
The plasma and buffy coat were discarded and the cells washed 3 times
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in PBS. The cell concentration was adjusted to 20x10 per ml in PBS.
1/100 rabbit anti-SRBC antiserum in PBS was added in equal volume to
SRBC in PBS, and incubated at 37°C for 30 minutes. After washing in
Eagle's medium, the sensitized cells were resuspended in Eagle's medium.
2.2.8.2. Preparation of radiolabelled Clq
Clq was kindly donated by Dr. K. Reid, Biochemistry Department,
Oxford University. The concentration was adjusted to 1mg/ml in
phosphate buffer (o.1M, pH7) and the Clq radiolabelled with *^I as
described in 2.2.5.
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2.2.8.3- Sensitivity of Clq deviation test
Aggregated human IgG was added at various concentrations (2pg/ml-
2mg/ml) to fresh normal human serum. 50pl of serum alone or serum
containing aggregates were added to 100pl saline and 100pl sucrose
veronal buffer and mixed in LP3 tubes. The mixture was heat inactivated
at 56°C for 30 minutes. 10pl of BSA in phosphate buffer (0.1M, pH7)
containing 1pg radiolabeled Clq was added, and the mixture was
g
incubated for 15 minutes at room temperature. Sensitized SRBC (4x10 )
were added and the suspension incubated for 15 minutes at room
temperature. After centrifugation at 400g for 5 minutes the
radioactivity in the supernatents and in the pellets was determined
using an automatic gamma counter (Wallac).
The percentage of inhibition of binding of radiolabelled C1q to
the pellet was calculated as follows:
cpm pellet
i Calculation of uptake = X 100
cpm pellet + cpm supernate
% uptake (serum alone) - % uptake
(serum + aggregates)
ii Calculation of inhibition = X 100
% uptake (serum alone)
2.2.9- Ra.ji cell radioimmunoassay
2.2.9-1- Preparation of cells
The first sample of cultured Raji cells was kindly donated by
Miss Judith Evans from Dr. C.M. Steel's laboratories in the MRC
Clinical & Population Cytogenetics Unit, Western General Hospital,
Edinburgh.
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Cells were cultured at 37°C in glass bottles in supplemented
Eagle's medium (see 2.2.1.). The cells were subcultured at 2-7 day-
intervals by dividing the contents of each glass bottle into two and
reconstituting to the original volume with culture medium.
2.2.9.2. Assay procedure
All sera were tested in duplicate. 2x10^ Raji cells in 50ql
Eagle's medium were incubated in LP3 tubes with 25ql of a 1:4
dilution of the test serum in saline.
After 45 minutes incubation at 37°C, the cells were washed 3
times in Eagle's medium and incubated at 4°C for 30 minutes with
125 ^
approximately I5pg of I goat anti-human IgG in 30pl 1% BSA in
125
phosphate buffer (0.1M, pH7). Unbound I-antiserum was removed by
3 washes with 1% BSA in PBS, and the radioactivity in the cell pellet
was counted in an automatic Gamma-counter.
The amount of uptake was referred to a standard curve of
radioactive antibody uptake by cells incubated with 25pl of 1:4
dilution of pooled normal human serum, to which varying amounts (from
50ng to 25pg) of aggregated IgG had been added. The amount of
complexes in each serum tested was expressed as jag aggregated IgG
equivalents per ml of serum (pg eq.AgglgG).
2.2.9.3. Detection of immune complexes after blocking Fc receptors
on Ra.ji cells
2x10^ Raji cells were incubated with 50ql of normal rabbit serum
(NRS) at 37°C for 1 hour. The cells were washed with Eagle's medium
3 times and incubated at 37°C for 45 minutes with 25pl of 1:4
dilutions of Hashimoto and control sera. The cells were then washed
125
with Eagle's medium and incubated with l5pg of I goat anti-human
AG
IgG antibody in 30jil *\% BSA in PBS in phosphate buffer (0.1M, pH7).
The cells were washed with 1% BSA in PBS and the amount of radiolabelled
antibody bound to the cells was counted. The amount of complexes in
each serum sample was estimated by referring to a standard curve of
radiolabel uptake by cells preincubated with NRS and incubated with
varying amounts of aggregated IgG.
2.2.9.A. Characterization of immune complexes
25pl of 1 :A dilution of sera from thyroid patients which were
found positive for the presence of immune complexes and their controls
were incubated with 2x10^ Raji cells at 37°C for A5 minutes. The
cells were washed 3 times with Eagle's medium and incubated with 15bg
125
of I rabbit anti-human thyroglobulin antibody in 30pl 1% BSA in
phosphate buffer (0.1M, pH7) at A°C for 30 minutes. The cells were
washed 3 times with BSA in PBS and the label bound to the cell
pellet was counted. The difference in the count between patients'
sera and their controls was estimated.
2.2.10. Rat spleen leucocyte radioimmunoassay
2.2.10.1. Preparation of rat spleen leucocytes (RSL)
9-15 week old male rats (Liverpool Hooded) were killed by
asphyxiation in a carbon dioxide atmosphere. The spleens were
removed and gently hand-homogenised in a small volume of Eagle's
medium.
The cell suspension was decanted and centrifuged at AOOg for 5
minutes. The cells were resuspended in Eagle's medium and left
undisturbed for TO minutes to allow coarse debris to settle. The
supernatatant was centrifuged at AOOg for 5 minutes and the cells were
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resuspended in 10ml Eagle's medium. The leucocytes were counted and
the suspension adjusted to the required concentration.
2.2.10.2. Preliminary observations
In order to detect and quantitate immune complexes in serum
using the RSL radioimmunoassay, it was necessary to construct a standard
curve of radiolabelled uptake by RSL incubated with varying amounts
of aggregated human IgG. 4x10^ RSL in lOOpl Eagle's medium were
incubated for 1 hour at 37°C with 50pl NHS or medium to which varying
amounts (2jig-4mg/ml) of aggregated IgG had been added. The cells were
washed 3 times with Eagle's medium and incubated for 30 minutes at 4°C
with 30pl 1% BSA in phosphate buffer (0.1M, pH7) containing approximately
125
I5pg I anti-human IgG antiserum. The cells were then washed with
1% BSA in PBS and the radioactivity bound to cell pellet was determined.
When RSL were incubated with aggregated IgG in fresh normal human
serum, the degree of binding was found to be extremely low. Dilution
of the serum resulted in an increase in binding for a given amount of
aggregated IgG. The possibility that complement activity was
responsible for these observations was investigated using chelating
_| _j |_
agents to inactivate the complement by complexing with Ca and/or Mg
ions. The classical pathway of complement requires the presence of
_| |_
both ion species, while the alternative pathway requires only Mg
ions.
Ethylenediamine tetra-acetic acid (EDTA), which complexes with
_| |_ |_
Mg and Ca , was used to inactivate complement by interfering with
both the classical and alternative pathways, while ethyleneglycol
|_
bis-(aminoethyl) tetra-acetic acid (EGTA), which binds to Ca and not
|_
to Mg , was used to block the classical pathway only.
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Serum samples from 2 normal subjects were dialysed at 4°C against
2 changes of complement fixing diluent buffer (CFD) (appendix II),
CFD containing 20mM EDTA and CFD containing 20mM EGTA. Aggregated IgG
was added to the dialysed sera to a concentration of 256 or 64pg/ml,
and assayed for binding to RSL.
In addition, the incubation of RSL with NHS resulted in
agglutination of erythrocytes present in the spleen cell preparation.
Accordingly, experiments were carried out to detect the presence of
anti-rat erythrocyte antibodies in human serum and to determine the
effect of these antibodies on the RSL radioimmunoassay. Serum
samples were obtained from 40 normal subjects, of whom 20 were blood
donors attending the Blood Donor Centre, Royal Infirmary, Edinburgh.
The remainder were hospital employees and laboratory workers. 5ml of
blood was aspirated from the vena cava of a rat, heparinized (10u/ml)
and centrifuged at 300g for 10 minutes. The plasma and buffy coat
were discarded and the cells were washed 3 times in PBS. Each serum
sample was tested for the presence of anti-rat erythrocyte antibodies
by incubating 20pl neat or serially diluted (1:2 to 1:256) serum with
20pl 2% rat erythrocytes in PBS at room temperature overnight. Known
amounts of aggregated IgG were added to NHS samples before and after
absorption of the sera with an equal volume of packed rat erythrocytes
and the sera tested in the RSL assay.
The results of these preliminary experiments indicated the
necessity of removing complement activity and anti-rat erythrocyte
antibodies before testing sera for the presence of complexes.
Accordingly all sera tested in the RSL radioimmunoassay were treated
with EDTA and absorbed with packed rat erythrocytes before use.
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2.2.10.3. Assay procedure for the detection of soluble complexes
6
4x10 RSL in 100pl Eagle's medium were incubated for 1 hour at
37°C with 50pl of test serum previously treated by the addition of
1 volume 100mM EDTA to 9 volumes serum and absorbed with packed rat
erythrocytes.
The cells were washed 3 times in Eagle's medium and incubated for
30 min at 4°C with 30pl 1% BSA in phosphate buffer containing
125
approximately I5pg I anti-human IgG antiserum. The radioactivity
bound to the cell pellet was referred to a standard curve of radio¬
active antibody uptake by RSL incubated with 50pl inactivated and
absorbed pooled NHS to which varying amounts (from 2pg-4mg/ml) of
aggregated IgG had been added.
2.2.10.4. Detection of anti-rat antibody in human sera absorbed with
rat erythrocytes
In order to determine whether one absorption of human sera with
rat erythrocytes was sufficient to remove anti-rat antibody activity,
the sera were tested for binding to RSL and to thymocytes after one or
two absorptions with rat erythrocytes or one absorption with rat
erythrocytes and one with thymocytes. Rat thymocytes were prepared
by hand homogenising the thymus in a few ml of Eagle's medium using a
glass homogenizer.
After absorption with equal volumes of rat erythrocytes and/or
thymocytes, the sera were assayed for binding to RSL or thymocytes.
50pl of serum were incubated for 1 hour at 37°C with 4x10^ RSL or
4x10^ thymocytes. The cells were then washed three times with Eagle's
medium and incubated for 30 min at 4°C with 15pg of radiolabelled
anti-human IgG antibody in 30pl of 1% BSA in phosphate buffer (0.1M,
pH7). The cells were washed 3 times with 1% BSA in PBS and the
activity of each cell pellet was determined.
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In a further experiment to confirm that the binding of absorbed
positive test sera to RSL was due to the presence of complexes and not
to residual anti-rat antibodies, the RSL were pretreated with aggregated
rat IgG in order to block the Fc receptors. The cells were incubated
for 1 hour at 37°C with 50pl of rat serum which had been aggregated by-
heating at 63°C for 15 minutes, and then washed 3 times with Eagle's
medium. 50pl volumes of sera found positive for complexes in the RSL
assay and of their corresponding controls were incubated for 1 hour at
37°C with 4x10^ of the pretreated cells, or with 4x10^ untreated cells.
After incubating with radiolabelled anti-human IgG antibody the activity
of the cells were determined as described above.
2.2.10.5. Effect of heat inactivation
The amount of aggregate formed by heat inactivation of human
serum was assayed using serum samples obtained from 20 normal donors
(F11, M9, Age 21-59, mean 37.5). Each serum sample was treated with
lOmM EDTA and absorbed with rat erythrocytes and divided into 2
aliquots, one of which was heated for 30 minutes at 56°C. Each
aliquot was then assayed in duplicate for the presence of complexes as
described in 2.2.10.3.
2.3. STATISTICAL ANALYSES
For the analysis of the data obtained using the ADCC inhibition
assay (percentage inhibition, IgG levels), Student's t test was used.
The incidences of immune complexes detected in sera from patients and
controls using the Raji cell radioimmunoassay were compared using the
Chi-squared test. The association between the presence of immune
complexes and anti-islet cell antibodies or anti-insulin antibodies in
51
the sera of diabetics was determined using Fisher's exact test and
the Chi-squared test respectively. The Chi-squared test was also
used to compare the incidence of late diabetic complications in
insulin-treated diabetics found positive or negative for the presence
of circulating immune complexes. The prevalence of anti-Coxsackie B4
antibodies in patients and controls were compared using the McNemar
Test. Differences among the counts obtained in the RSL assay using
serum absorbed once or twice with rat erythrocytes and/or rat
thymocytes were compared using Student's t test. The Wilcoxon Rank
Sum Test was used to compare the quantity of complexes detected in
Hashimoto sera using Raji cells untreated or pre-treated with normal
rabbit serum.
RESULTS
3.1. INHIBITION OF ADCC
3.1.1. ADCC mediated by rat spleen cells
Rat spleen cells were shown to have considerable ADCC activity.
The spleens from each of 6 rats were homogenized and the cells
incubated on glass at 37°C for 2 hours. The concentration of cells
in each suspension was adjusted to 20x10 /ml. 20pl of 2x10 /ml Cr -
labelled CRBC were incubated with 200pl rat spleen cell suspension at
five different dilutions in order to obtain effector cell/target cell
ratios of 6.25:1, 12.5:1, 25:1, 50:1 and 100:1. Tubes were set up
in two sets of triplicates.
-3 -3
I00pl anti-CRBC antiserum at concentrations of 2x10 and Ax10
were added to each set of triplicates. The cytotoxicity mediated by
the effector cells in each tube was calculated according to the
following formula:
51
Cr release by effector cells
cytotoxic index = X 100
maximum release
51
The maximum release of Cr from labelled target cells was obtained
by lysis with distilled water. The cytotoxic index for each effector
cell/target cell ratio at each of the two concentrations of anti-CRBC
antiserum is shown in Figure 1. With increasing numbers of effector
cells, the degree of cytolysis increased, reached a maximum and then
declined. In further studies, effector/target cell ratios of 20:1
and 50:1 were used.
3-1.2. The effect of antibody concentration on cytotoxicity
Rat spleen cells and target cells at ratios of 20:1 and 50:1
were incubated with various dilutions of anti-CRBC antiserum. The
54
Fig. 1 The cytotoxic indices at various effector/target cell
ratios using two different concentrations of anti-CRBC
antiserum. Each point represents the mean and standard
error obtained using spleen cells from six individual rats.
_3
Upper line: antibody concentration of A x 10 ; lower
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cytotoxic indices obtained are shown in Figure 2. At low antiserum
concentrations (10 2x10 the degree of cytotoxicity was negligible:
increasing the antiserum concentration resulted in a linear increase in
the cytotoxic index to a maximum of 75% (50:1) and 65% (20:1 )._at a
_2
concentration of 10
On the basis of these results, the conditions initially chosen
for the inhibition of ADCC were as follows: 20:1 effector/target cell
_3
ratio, 2x10 antibody concentration. This gave a cytotoxic index of
45%.
3.1.3. Sensitivity of the inhibition assay
Aggregated and preformed complexes were used to investigate the
sensitivity of the ADCC inhibition assay.
3.1.3-1. Sensitivity of the assay to ovalbumin-antiovalbumin complexes
The precipitate formed by the interaction of 312pg/ml ovalbumin
and neat antiserum was dissolved in 0.2ml PBS and 50pl of this solution
was diluted by PBS to 2ml. The protein concentration of the solution
was estimated using a Zeiss spectrophotometer at 280nm. The solution
was diluted to 600pg/ml using 1/10 heat inactivated serum. 100pl of
this solution and of 1/2, 1/4, 1/8 dilutions of this solution were
added in triplicate to 200pl of 10x10 rat spleen cells and the
suspensions incubated at 37°C for 2 hours in an atmosphere of 5% CO2
_3
in air. After incubation with 100ji1 4x10 anti-CRBC antiserum and
6 51
20pl 2x10 Cr -labelled target cells for 18 hours, the degree of
inhibition of isotope release was calculated as described in 2.1.9.
As shown in Figure 3, there was a linear increase in the percentage
inhibition with increasing amounts of antigen-antibody complexes.
Fig- 2 The cytotoxic indices at two effector/target cell ratios
using various dilutions of anti-CRBC antiserum. Each
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Fig. 3 Percentage inhibition of ADCC by ovalbumin -antiovalbumin
complexes. Each point represents the mean and standard
error of five experiments using 600pg/ml added complexes in
1/10 heat-inactivated normal human serum and serial dilutions
in medium.
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3.1.3.2. Sensitivity of the assay to aggregated IgG
Heat-inactivated normal human serum was diluted with Eagle's
medium to 1/10, 1/20, 1/40 and 1/80. Aggregated IgG was added to each
of these serum dilutions and to medium alone, to give concentrations of
100, 50, 25, 12.5, 6.25 and 3.125pg/ml. lOOpl of medium and serum
containing aggregates were added in triplicate to 200pl 10xl0^/ml rat
spleen cells. After incubation at 37°C for 2 hours in an atmosphere
of 5% CO2 in air, anti-CRBC antiserum and target cells were added as
described in 3.1.3.1.
The mean percentage inhibition in each triplicate was calculated
and the values obtained in 6 experiments using various concentrations
of aggregated IgG in medium alone are shown in Figure 4. With
increasing amounts of aggregated IgG there was a linear increase in
the degree of inhibition of ADCC. The mean percentage inhibition
obtained in 6 experiments using various concentrations of aggregated IgG
in different dilutions of heat-inactivated normal human serum is shown
in Figure 5- The degree of inhibition increased with increasing
amounts of aggregated IgG at all dilutions of serum. The limit of
detection was approximately 25pg/ml of added aggregated IgG, or a final
concentration of 6.25pg/ml. The degree of inhibition of ADCC at low
concentrations of serum was higher than with other dilutions of serum.
This appears to be due to the fact that a 1/10 dilution of normal serum
itself significantly inhibited ADCC. This inhibition was greatest
_3
when using a 20:1 cell ratio and antiserum dilution of 2x10
(Figure 6). "The sensitivity of the assay was therefore approximately
■250 bg/ml in neat serum.
3.1.4. Inhibition of ADCC by sera from patients with thyroid disorders
u
Sera from twenty five patients with Hashimoto thyroiditis, twenty
nine patients with primary hypothyroidism, twenty six patients with
Fig. A Percentage inhibition of ADCC by various concentrations
of aggregated IgG. Each point represents the mean and
standard error for six experiments. The effector/
target cell ratio was 50:1, and the antibody concentration
_3
was A x 10
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Fig. 6 Percentage inhibition of ADCC by serial dilutions of heat
inactivated normal human serum using two effector/target
cell ratios.


















untreated thyrotoxicosis and twenty seven patients with treated
thyrotoxicosis were tested in triplicate for inhibition of ADCC, using
1/10, 1/20, 1/40 and 1/80 dilutions of each serum. The results are
shown in Table 1. Significantly, increased inhibitions were obtained
with all dilutions of the sera of patients with Hashimoto thyroiditis
or hypothyroidism, as compared with age- and sex-matched controls,
whereas no significant inhibition was found with the thyrotoxic group,
except at the two lowest dilutions of sera. To produce similar
degrees of inhibition, control sera had to be used at concentrations of
more than twice that of Hashimoto thyroiditis or hypothyroid sera.
3-1.5- Determination of serum IgG levels
Increased inhibition of ADCC by patients' sera could result from
factors other than the presence of immune complexes, including increased
levels of IgG. To investigate this possibility, determinations of IgG
levels were carried out on the sera used in the inhibition assay.
The results are shown in Table 2. Significant elevations of IgG
levels were found in two groups, the greatest elevation being in the
Hashimoto thyroiditis patients. A smaller increase was found in the
untreated thyrotoxic patients, while patients with primary
hypothyroidism or with treated thyrotoxicosis had serum IgG levels
similar to those of their age- and sex-matched controls.
3.1.6. Correlation of inhibition with IgG levels in the test sera
In order to determine whether the inhibition observed was
related to the level of IgG in the test sera, the percentage inhibition
was compared with serum IgG concentration. The results of this
comparison are shown in Figures 7 and 8. It will be observed that
there was no correlation between percentage inhibition and IgG levels.
Table1Percentageinhibition(mean-SE)ofADCCbys rafr mp tie tsw tht yr iddi ord r „,No.fSampleDilutionofserum samples1Q2g0 Hashimoto thyroiditis253 -4-354P<0.0014. ^2.841 .0±1.921 7- .700.0 controls250.5-1.9910.2±1.425-40^0 87.56-O A8 primaryhy o-" thyroidism299.6-3.09P<0.00119.9-2.23<0 111.5-1 95C0.7.03 1.585 controls2916.5-1-950 3 .45-90^0.913. 0 78 untreated thyrotoxicosis264.0^2.12N.S.15-5 00P<0 57.16-1.313.08-1.0. . controls2617.0±2.639.95^ .046.50-1.513.16 0 99 treated thyrotoxicosis276.4-3.31N.S.17.2 2.469-00 1 584.50-0.9 controls2719.3-1-920.8±'1.505. 0^1. 33.1 ^0 84 N.S.=notsignificant





















Fig.7CorrelationfpercentageinhibitionfADCCbysefr mpati n swithHas motthyroid isnd hypothyroidismwitht eIgGlevelfesesera.Standa drrorsofthmeanarshowb horizontalandverticalba s. ■70 +:••Hashimotothyroiditis •Primaryhypothyroidism ito"180""200"L_ 220 mg/100lSERUMIgG1 240-1i,26083002
ON
N_Tt






















In certain instances sera which were highly inhibitory contained low
levels of IgG, while in other cases sera with high levels of IgG gave
a low percentage of inhibition.
3.1.7. Correlation of inhibition with the IgG levels of both test
and control sera
The percentage inhibition and IgG levels at each of the four
dilutions of test serum were compared with those of the controls.
Figure 9 shows the mean percentage inhibition and the mean IgG
levels in Hashimoto and control sera at the four dilutions of serum
used. Figures 10 - 12 show the corresponding data for primary
hypothyroidism, untreated thyrotoxicosis and treated thyrotoxicosis
respectively together with their controls. It is apparent that, at
the same level of IgG, sera of patients with Hashimoto thyroiditis or
hypothyroidism are markedly more inhibitory than those of the controls.
On the other hand, differences between the sera of thyrotoxicosis
patients and_their controls are only slight.
3-1.8. Inhibition of ADCC by serum fractions
Serum fractions obtained by passing serum samples through
Sephadex G-200 were assayed for inhibitory activity.
3-1.8.1. Hashimoto sera
Three Hashimoto sera and their controls were fractionated and
assayed for inhibitory activity. The results using fractions from
one Hashimoto serum are shown in Figure 13- These indicate that the
greatest inhibition was found in fractions located in the ascending
limb of second elution peak. Negligible inhibitory activity was
Fig.9Correlationfinhib tionADCCbyserfr mpati ntswithHashimotothy o d tisndt econtrols withIgGlevels.Eachserumwate t datdilutionof1/10,240and/8forinhibition ofADCC.Eachpointrepresentsthmeaandsta d rde r rfo25individu ls.Uppl n : patients;lowerin :controls.(Datfr mt blesId.2.)
o
00
Fig-12CorrelationofinhibitionfADCCbyserafr mpatientswithprimaryhy othyroidismndt ei controlswithIgGlevel .Eachserumwastestedtdilutionf1/10,1/2 ,4a d1/80 forinhibitionofADCC.Eachp intrepresentsthmeana dstandardrrorfo29indivi uals. Upperlin :atients;low rlin :controls. mg/100lSERUMIgG
0N
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Fig.11CorrelationfinhibitionADCCbys rafr mpat entswithunt ea edthyrot xicosisa dt e controlswi hIgGlevels.Eacserumwate t ddiluti nof1/10,2/40and8f inhibitionofADCC.Eachpointrepresentsthmeaandst d rder orfo26individuals. Upperline:ati nts;low ri :controls. 50P- 40_&1/10dilutionofserum □1/20dilutionofserum o1/40dilutionfserum •1/80dilutionofserum u u Q < In o £ 2 £ CP HH 530- 20 10- 4068 mg/100lSERUMIgG100120
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observed in the second elution peak of the control serum. Similar
3 of
results were obtained from the^other Hashimoto sera and their controls.
Fractions obtained from heat-inactivated Hashimoto sera showed
additional inhibition in the first elution peak as shown in Figure 14.
Similarly, heat-inactivation of control serum resulted in the
appearance of inhibitory activity in the first peak. These observations
suggest the presence of aggregates formed as a result of heat
inactivation. Other 4 Hashimoto Sera gave inconclusive results.
3.1.8.2. Hypothyroid serum
The inhibition of ADCC by fractions of hypothyroid serum is shown
in Figure 15. Inhibitory activity was detected in the ascending
limb of the second elution peak. The degree of inhibition by these
fractions was less than that of the comparable fractions of Hashimoto
sera.
3.1.9. Correlation of ADCC inhibition by sera from patients with
thyroid disorders with their clinical data
The results of serological investigations of each serum for the
presence of anti-thyroid antibodies using the TCH and CFT techniques
and for the presence of anti-microsomal antibody (IC), and anti-
parietal cell antibody (PC) were compared with the capacity of the
serum to inhibit ADCC.
As shown in Tables 3, 4, 5 and 6, no correlation was found between
the percentage inhibition (which was regarded as positive if the
percentage inhibition in the test serum was more than that of the mean
of the controls or of its particular control, whichever was the
greater), and the presence or levels of the antibodies investigated.
Similarly, the degree of inhibition could not be correlated with the
duration of illness (date of diagnosis to date of study).
Fig.14Chromatographyfheat-inactivatedH shim tondco rolernS p dexG-200owingt percentageinhibitionofADCCassoc atedw theachfract on.
Fig.15Chromatographyfseraf ompatientw thp imaryhypothyroidismndsco rolSepha exG-200 showingIgGcontenta dt perc ntagein ibitionfADCCassociatedthchfr c on. IgG;*—•percentageinhibition. Primaryhypothyroidism 20L 40_ Control 30 20









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.2. Clq DEVIATION TEST
3.2.1. Sensitivity of the Clq deviation test to aggregated IgG
125
The deviation of I C1q binding to sensitized sheep erythrocytes
by Clq-reactive material in the form of aggregated IgG added to pooled
normal human serum was measured by comparing the amount of radio-
labelled Clq bound to the indicator cells with that detected in the
125
supernatant. I Clq was found to deviate from binding to sheep
erythrocytes in the presence of aggregated IgG (Figure 16) and also in
the presence of heat-inactivated serum.
The results indicate that this assay is relatively insensitive,
since the lower limit of detection of added aggregates was approximately
100p.g/ml. Moreover, this limit of detection varied according to the
human serum used (Figure 17).
3.3. RAJI CELL RADIOIMMUNOASSAY
3.3.1. Antibody activity of fractionated anti-human IgG antiserum
Anti-human IgG antiserum was fractionated on DEAE cellulose as
described in 2.2.3., and the fractions (Figure 18) tested for antibody
activity.
Antibody activity was found in all fractions of the first and
second elution peaks. However, this activity was lower than that
shown by the solubilized precipitate formed by treatment of the
antiserum with ammonium sulphate, even after bulking and concentration
of the fractions. Accordingly, iodination of anti-human IgG antibodies
was carried out using the proteins isolated by ammonium sulphate
precipitation.
81
Fig. 16 Deviation of radiolabelled Clq from binding to sensitized
sheep erythrocytes by various amounts of aggregated IgG
added to normal human serum. Each point represents the
mean and standard error of four experiments.
Mg/ml AGGREGATED IgG
Fig. 17 Deviation of radiolabelled Clq from binding to sensitized
sheep erythrocytes by various amounts of aggregated IgG
added to each of five normal human sera.
100
/jg/ml AGGREGATED IgG




















3-3.2. Optimal conditions for the assay
Increasing amounts of radiolabelled anti-human IgG were added to
£
a constant amount of aggregated IgG bound to 2x10 Raji cells. As
shown in Figure 19, 30jil of 1% BSA in phosphate buffer containing
approximately 15pg radiolabelled anti-human IgG was found to give the
highest level of specific uptake-{uptake by cells incubated with NHS
and added aggregated IgG minus uptake by cells incubated with NHS
alone).
3.3.3. Sensitivity of the assay to aggregated IgG
The sensitivity of the Raji cell radioimmunoassay in detecting
immune complexes in serum was estimated by adding different concentrations
of aggregated IgG to a 1:4 dilution of pooled normal human serum, and
measuring the uptake of label after incubation with 30pl of 1^ BSA in
phosphate buffer containing 15pg radiolabelled goat anti-human IgG.
At a concentration of 6pg/ml in 1:4 dilution of serum the uptake of
radiolabelled antibody by the Raji cells was considerably greater than
that using serum alone. The amount of radiolabelled antibody taken
up by the cells was directly related to the amount of aggregated IgG
present in the serum as shown in Figure 20. The sensitivity of the assay
was therefore 2.4 pg/m I in neat serum.
3.3.4. Detection and quantitation of immune complexes in sera of
patients with thyroid disorders
Raji cells were incubated with twenty-three Hashimoto, twenty-eight
hypothyroid, and twenty thyrotoxic sera and then reacted with an optimal
amount of radiolabelled anti-human IgG. Subsequently the uptake was
determined and referred to a standard curve of radioactive antibody
uptake by cells previously incubated with various amounts of aggregated
IgG in a 1:4 dilution of serum (Figure 20). The radiolabelled
Fig. 19 Titration of radiolabelled anti-human IgG for the
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Fig. 20 Standard curve of radiolabelled anti human IgG bound to
untreated or NRS-treated Raji cells incubated with various
amounts of aggregated IgG. Each point represents the mean






antibody uptake by cells incubated with a 1:4 dilution of pooled NHS
was considered as a baseline in the reference curve. The estimated
amount of complexes in each serum tested was expressed as ug
aggregated IgG equivalents per ml serum (pg eq.AgglgG/ml). More than
6pg eq. AgglgG/ml, a level exceeding the upper limit of controls, was
found in 1:4 dilutions of 78% Hashimoto, 36% hypothyroid and 20%
thyrotoxic sera (Table 7). The results indicate that the greatest
amount of complexes was detected in sera from patients with Hashimoto
thyroiditis.
3.3.5. Detection and quantitation of immune complexes in Hashimoto
sera after blocking the Fc receptors on Ra.ji cells
The binding of immune complexes to Raji cells is mediated via
complement receptors and Fc receptors. The latter receptor also
binds monomeric IgG, and sera of patients with Hashimoto thyroiditis
contain higher levels of IgG than control sera. Therefore, to avoid
false positive results which might arise due to the binding of
monomeric IgG to Fc receptors on the Raji cells, the cells were pre-
incubated with NRS for 1 hour at 37°C in order to block Fc receptors
by monomeric rabbit IgG. The cells were then washed and incubated
with a 1:/| dilution of test and control sera for 45 minutes at 37°C.
125
After washing the cells 3 times with Eagle's medium, 30pl of I goat
anti-human IgG were added. Unbound antibody was removed by washing
the cells 3 times with 1% BSA in PBS. The amount of complexes bound
to the cells was estimated by referring to a standard curve of
radioactive antibody uptake by cells pre-incubated with NRS, and
subsequently incubated with various amounts of aggregated IgG in a
1:4 dilution of pooled normal human serum (Figure 20). It will be
observed that the blocking of the Fc receptors on Raji cells led to






















a reduction in the amount of radioactivity bound to these cells. This
suggests that the binding of monomeric human IgG to Raji cells was
prevented by pre-incubating these cells with NRS.
The amount of complexes detected in each serum sample using Raji
cells pre-treated with NRS was compared with that detected using
untreated Raji cells. As shown in Table 8, the blocking of Fc
receptors did not significantly affect the degree of binding of
complexes to the cells.
3.3.6. Characterization of immune complexes
Sera from eighteen patients with Hashimoto thyroiditis, ten
patients with primary hypothyroidism and four patients with
thyrotoxicosis found positive for the presence of soluble immune
complexes were incubated with Raji cells. The cells were then
125
incubated with I-rabbit anti-human thyroglobulin antiserum in order
to test for the presence of thyroglobulin in the bound complexes. As
shown in Figure 21, the degree of binding of radiolabelled anti-human
thyroglobulin antibodies to Raji cells incubated with 8 out of 18
Hashimoto sera and 3 out of 10 hypothyroid sera was higher than that
detected using Raji cells incubated with control sera.
3.3.7. Correlation of clinical data of patients with thyroid disorders
with the presence of immune complexes in their sera
The results of serological investigations of each serum for the
presence of anti-thyroid antibodies using the TCH and CFT techniques
and for the presence of anti-microsomal antibody (IC) and anti-parietal
cell antibodies (PC), together with the duration of the illness (date
of diagnosis to date of study) and the treatment, if any, were
compared with the presence and the amounts of immune complexes
Table 8 The binding of complexes present in the sera of patients
with Hashimoto thyroiditis to untreated Raji cells and to


























Mean ± SE 200 ± 40.54 165 ± 34.41
P> 0.25







detected by the Raji cell radioimmunoassay. The results indicate
that no correlation exists between serological findings, duration and
treatment and the presence or absence of immune complexes in the sera
of patients with Hashimoto thyroiditis (Table 9), with primary
hypothyroidism (Table 10) and with thyrotoxicosis (Table 11).
3.3.8. Detection and quantitation of immune complexes in diabetic sera
Raji cells were incubated with sera from thirteen newly diagnosed
insulin-dependent diabetics, thirty-two insulin-treated diabetics,
thirty-one diabetics treated with oral hypoglycaemic agents (OHA) and
twenty-one diabetics requiring restriction of diet alone. Sera from
53-8% of newly diagnosed, 53% insulin-treated, 9.6% OHA-treated and
9-5% diet-treated diabetics were found to have immune complex-like
activity exceeding the limit of controls (Table 12).
3.3.9. Detection of anti-viral antibodies in sera of newly diagnosed
diabetics
The sera of the thirteen newly diagnosed insulin-dependent
diabetics and their age- and sex-matched controls were screened and
titrated for antibodies to common viral infections, as shown in Table
13. The prevalence and titres of antibodies to all viruses
investigated other than Coxsackie B4 were similar in diabetics and in
their controls. Coxsackie B4 antibodies were found in 6 out of 13
test sera compared with only 2 out of 13 controls, but this difference
between the two groups was not significant.
3.3.10. Correlation of the presence of anti-islet cell antibodies,
anti-Coxsackie B4 antibodies and immune complexes
All diabetic sera were investigated for the presence of anti-islet
cell antibodies.
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The occurrence of soluble immune complexes in the sera of seven
out of thirteen newly diagnosed insulin-dependent diabetics exhibited
a high degree of correlation with the presence of anti-islet cell
antibodies (p<O.Ol) while no correlation was found with the prevalence
and titre of anti-Coxsackie B4 antibodies.
3-3.11- Detection of anti-insulin antibodies
All diabetic sera were tested for the presence of anti-insulin
antibodies. No antibodies were detected in the newly diagnosed
insulin-dependent diabetics.
The sera of all the thirty-two diabetics treated with bovine or
porcine insulin had increased insulin-binding activity indicating the
presence of antibody to insulin. The titre varied from 26-286pU/ml
irrespective of the duration of insulin therapy (between 2-42 years),
the dosage of insulin used or the sex of the patient (Figure 22). The
sera of all insulin-independent diabetics were negative for anti-
insulin antibodies.
3-3-12. Correlation of the titre of anti-insulin antibodies and the
presence of complexes and duration of treatment
All patients with high titres of anti-insulin antibodies
(>300uU/ml) had soluble immune complexes in their serum (Figure 23).
When the insulin-treated diabetics were subdivided according to
whether they developed diabetes before or after the age of 30 years,
immune complexes were found more frequently in the presence of
moderate titres of anti-insulin antibodies in the early onset, compared
to the late onset, diabetics (p<0.05) (Figure 24). Immune complexes
occurred more commonly in patients treated with insulin for 10 years or
more (16 out of 23) than in those receiving insulin for less than 10
years (1 out of 9) (p<0.001).
Fig.22Thecorrelationbetw et ccurrencefimm nomplex sandinsulinantibo ieshhirty-two insulin-treateddiabeticsandthdurationofnsulitreatm nt. 600positivef rc mplexes negativeforcomplexes 500 400 300 £9200 1001-o•# O•°. /• I _LJLJI 5105234 DURATIONOFINSULITREATMENT(Y RS)
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Fig. 23 The correlation between the titre of insulin antibodies and
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Fig. 2A The prevelance of immune complexes and titres of insulin
antibodies in insulin-treated diabetics according to the
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3.3.13. Diabetic complications and the presence of complexes
Thirty-two insulin-dependent diabetics were examined for
clinically manifested complications including diabetic retinopathy
(defined by the presence of more than 3 microaneurisms, retinal
haemorrhages, exudate or new blood vessel formation), or diabetic
nephropathy (defined by a permanent proteinurea with or without
abnormal kidney function).
As shown in Figure 25, sixteen patients had complications, and
twelve of these had soluble immune complexes compared with only five
of the remaining sixteen patients. It was found that immune
complexes in the serum was associated with late diabetic complications
only in patients who had suffered from diabetes for more than 13 years.
High titres of anti-insulin antibodies (>300pU/ml) were
associated with the presence of diabetic complications. Four of the
six patients with insulin antibodies in the serum at a titre of
>300pU/ml had late diabetic complications and has suffered from
diabetes for 15 years or more. In the other two, the duration of
diabetes was 2 and 13 years respectively.
3.A. RAT SPLEEN LEUCOCYTE RADIOIMMUNOASSAY
3.A.1. Optimal conditions for the assay
3.A.1.1. Concentration of RSL
100ul volumes of different concentrations of RSL were incubated
with various concentrations of aggregated IgG in 50pl NHS inactivated
by 20niM EDTA and absorbed by rat erythrocytes or medium alone. The
cells were incubated for 1 hour at 37°C, washed 3 times with Eagle's
•i or
medium and then incubated at A°C for 30 min with 30pl I anti-human
103
Fig. 2$ The correlation between the amount of immune complexes and
the presence of late diabetic complications according to
the duration of diabetes in the thirty-two insulin-treated
patients.
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IgG. Unbound radiolabelled antibody was removed by washing the cells
in ^ BSA in PBS. As shown in Figure 26, 4x10 RSL was found to be
the optimal concentration of cells required for the assay. Further
experiments using other volumes of NHS (25pl, 100pl) did not detect
any increase in the sensitivity of the assay (Figure 27).
1253.4.1.2. Concentration of I anti-human IgG
Increasing amounts of radiolabelled anti-human IgG were added to
£
a constant amount of aggregated IgG bound to 4x10 RSL. As shown in
Figure 28, 30pl of 1% BSA in phosphate buffer containing approximately
I5pg radiolabelled anti-human IgG was found to give the highest level
of specific uptake (uptake by cells incubated with NHS and added
aggregated IgG minus uptake by cells incubated with NHS alone).
3.4.1.3. Incubation time
4x1o6 RSL in 100pl Eagle's medium were incubated with various
concentrations of aggregated IgG in 5Qul inactivated and absorbed
serum for 30 min, 1 hour, 2 hours or 4 hours. The cells were washed
and radiolabelled anti-human IgG was added. Figure 29 shows the
radiolabel uptake after each period of incubation. The degree of
binding was maximal at 1 hour.
3.4.1.4. EDTA concentration
The concentration of EDTA needed to inactivate the serum was
£
estimated. 4x10 RSL in 100pl Eagle's medium were incubated with a
constant amount of aggregated IgG added to 50pl inactivated and
absorbed serum. As shown in Figure 30, serum was totally inactivated
by 8mM EDTA. In all subsequent experiments, a final concentration of
10mM EDTA in serum was used.
26 The uptake of radiolabelled anti-human IgG by various
concentrations of RSL incubated with different amounts
of aggregated IgG. S = normal human serum.
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Fig. 27 The uptake of radiolabelled anti-human IgG by RSL incubated
with different volumes of normal human serum containing










28 Titration of radiolabelled anti-human IgG for the















Fig. 29 The uptake of radiolabelled anti-human IgG by RSL incubated
with various amounts of aggregated IgG: the effect of




































Fig. 30 Inactivation of normal human serum with various concentrations
of EDTA as shown by the effect on binding of a fixed amount
of aggregated IgG (16)ig/ml) to RSL. S = normal human
serum.
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3.-4.2. Standard curve and sensitivity of the assay
4x10^ RSL in 100pl Eagle's medium were incubated with 50pl pooled
NHS (inactivated with 10mM EDTA and absorbed with rat erythrocytes)
containing varying concentrations of aggregated IgG (2pg - 4mg/ml).
The amount of radiolabelled anti-human IgG bound to RSL was estimated
as described in 3.4.1.1. As shown in Figure 31, the radioactivity
£
bound to 4x10 RSL in medium containing 2pg/ml aggregated IgG was
higher than that bound to the same number of cells in medium alone.
Similarly the radioactivity bound to 4x10^ RSL in serum containing
4pg/ml aggregated IgG was higher than that bound to the same number of
cells in serum alone. The amount of radiolabelled antibody uptake by
the cells was directly related to the amount of aggregated IgG present
in the serum. In further experiments on the detection of immune
complexes or of aggregates present in human serum, the results were
referred to this curve and expressed as pg aggregated IgG equivalent
per ml (pg eq. AgglgG/ml). "The sensitivity of the assay was therefore 4ug/ml
in neat serum.
3.4.3. Binding of monomeric IgG to RSL
4x106 RSL in 100pl Eagle's medium were incubated with 50pl of
EDTA-inactivated and rat erythrocyte-absorbed NHS with or without
10mg/ml or 20mg/ml added IgG. Human sera with low, medium, and high
IgG levels were incubated in 50pl volumes with RSL after inactivation
and absorption. The binding of IgG to RSL was estimated by referring
to the standard curve of radiolabelled antibody uptake by RSL
previously incubated with various amounts of aggregated IgG in serum.
The results indicate that the difference in the uptake of label
between RSL incubated with serum of low and high IgG levels was
equivalent to approximately 4pg eq.AgglgG/ml. The difference in
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Fig. 31 Standard curve of radiolabelled anti-human IgG bound to
RSL incubated with various amounts of aggregated IgG
added to serum or medium. Horizontal bars indicate the
degree of binding of label to RSL incubated with two
different concentrations of monomeric IgG. Upper line:
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the uptake of label by cells incubated with NHS and those incubated
with NHS plus added IgG was equal to Apg eq.AgglgG/ml in the case of
10mg/ml added IgG, and 8pg eq.AgglgG/ml in the case of 20mg/ml
(Figure 31)•
3.A.A- Effects of complement on aggregates binding to RSL
Experiments were carried out to determine whether complement
activity present in NHS inhibits the binding of aggregated IgG to RSL
and/or induces the release of bound aggregates.
3.A.A.1. Inhibition of binding
Serum samples were dialysed against CFD or CFD containing a final
concentration of 20mM EDTA or EGTA. Aggregated IgG at 256 or 6Apg/ml
were added to the dialysed sera. The sera then were incubated for
1 hour at 37°C in 50pl volumes with 100pl medium containing Ax10^ RSL.
The binding of aggregated IgG to RSL was determined after incubation
with 30pl radiolabelled anti-human IgG.
The inactivation of serum with EGTA was found to have no effect
on the binding of aggregated IgG to RSL. In contrast, inactivation
with EDTA resulted In a significant increase in the degree of binding
compared to that found using serum dialysed against CFD alone
(Figure 32).
3.A.A.2. Release of bound aggregates
Aggregated IgG in medium (256 and 6Apg/ml) was incubated for 1 hour
at 37°C with Ax10^ RSL in 100pl medium. After washing the cells with
Eagle's medium and reconstituting the volume to 100pl, 50pl EDTA-
treated or heat-inactivated NHS were added to the cell suspensions.
The cells and added serum were incubated for 1 hour at 37°C, and
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Fig. 32 The uptake of radiolabelled anti-human IgG by RSL incubated
with medium or with serum containing aggregated IgG: the
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then the cells were washed 3 times with Eagle's medium. The degree
of binding of aggregated IgG to the cells was assessed as described
above.
As shown in Figure 33, the radiolabel uptake by RSL incubated with
aggregated IgG and subsequently with NHS was negligible and comparable
with that shown by RSL incubated with medium alone. In contrast, the
uptake by cells incubated with aggregated IgG and then with inactivated
sera was comparable with that of cells incubated with aggregated IgG
and not treated with serum. These results indicate that NHS induces
the release of bound aggregates from RSL. \
3.4.5. Formation of aggregates by heat treatment of serum
Serum samples obtained from 20 normal donors were inactivated
with 10mM EDTA and absorbed with rat erythrocytes. Each serum sample
was divided into 2 aliquots, one of which was heated at 56°C for 30 min.
50pl of each aliquot was incubated for 1 hour at 37°C with 4x10^ RSL
in 100pl Eagle's medium. The cells were then washed 3 times with
Eagle's medium and incubated at 4°C for 30 min with 30jil ^^1 airti_
human IgG.
1
By referring to a standard curve of radiolabelled antibody uptake
by RSL previously incubated with various concentrations of aggregated
IgG, the amount of aggregates formed in each serum tested was
determined. As shown in Figure 34, 0-128 (mean 37) pg eq.AgglgG/ml
were detected in the heat-treated normal sera.
3.4.6. Detection of anti-rat erythrocyte antibodies
Serum samples obtained from 40 human donors were tested by
haemagglutination assay for the presence of anti-rat erythrocyte
antibodies. 20pl neat or serially diluted (1:2 to 1:256) serum were
Fig. 33 The effect of fresh, heat-inactivated and EDTA treated
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Fig. 3L, The uptake of radiolabelled anti-human IgG by RSL
incubated with normal human sera: the effect of heat-
inactivation of the sera.






















incubated at room temperature overnight with 20pl 2% rat erythrocytes
in PBS. The results indicate that all sera tested had anti-rat
erythrocyte antibodies with titres up to 1:128 (Figure 35). 10 serum
samples from patients with thyroid disorders or diabetics were compared
with their controls for haemagglutination titre. No significant
differences were detected. The activity was completely removed by a
single absorption with rat erythrocytes.
3.4.7. Absence of residual anti-rat leucocyte antibodies in sera
absorbed with rat erythrocytes
Although one absorption with rat erythrocytes was effective in
removing all anti-rat erythrocyte activity from serum samples, the
possibility existed that residual antibodies directed toward other
antigenic determinants, for example those present on rat leucocytes,
could still be interferring with the RSL assay. Further experiments
were therefore carried out in which sera were absorbed once or twice
with rat erythrocytes or once with rat erythrocytes and once with
rat thymocytes and then tested for binding to RSL in the assay.
These extra absorption stages had no significant effect on the amount
of binding to RSL by any of the absorbed sera (74,230-6,940 cpm after
one absorption with rat erythrocytes; 72,700i6,270 cpm after two
absorptions; 70,576^4,320 cpm after one absorption with rat erythrocytes
and one with rat thymocytes). Further evidence that the elevated
levels of binding found in positive sera were due to the presence of
immune complexes and not to the presence of anti-leucocyte antibodies
was provided by an experiment in which binding of label was completely
inhibited by prior incubation of the RSL with aggregated autologous
rat IgG (Table 14).
Fig.35Anti-raterythrocytean ibodytitresoffo tno malhumanse a. 1/ 1/ 1/ 1/ b> 1/w1/w s h-3256 128 64 32 16 8 1/ SERUMAMPLES
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3. A. 8. Detection and quantitation of immune complexes in sera from
patients
RSL were incubated with sera from twenty-one Hashimoto, twenty-
eight hypothyroid and twenty thyrotoxic patients, and with thirteen
newly diagnosed insulin-dependent diabetics, thirty-two diabetics
treated with insulin, thirty-one diabetics treated with OHA, twenty-one
diabetics treated by restriction of diet and one hundred and sixty
normal controls. The sera were inactivated with lOmM EDTA and
absorbed with rat erythrocytes before being used.
Radiolabelled anti-IgG antibody was added to the washed cells.
The amounts of radioactivity bound to the cells were referred to a
standard curve of radiolabelled antibody uptake by cells previously
incubated with varying amounts of aggregated IgG. More than Apg
eq.AgglgG/ml were detected in 52.1% of sera from patients with thyroid
disorders and in 39-5% of diabetic sera (Table 15).
3.A.9. Comparison of results obtained using the RSL and Ra.ji cell
radioimmunoassays
The results obtained using the RSL assay were compared with those
obtained using the Raji cell assay. As shown in Table 15, a higher
percentage of sera tested were positive using RSL than using Raji
cells. In addition, the amounts of complexes detected by the Raji
cell radioimmunoassay were higher in all positive sera. All .sera found
positive using Raji cells were also positive by the RSL assay.































































































Speculation as to the role of immune complexes in the patho¬
genesis of disease has prompted many workers to attempt to develop
methods for the detection of these complexes. At the present time
there are a large number of methods available for 'the detection of
immune complexes in serum, although most if not all of these methods
are of limited value, for while they suggest that immune complexes may
be present, they can give no indication of the nature of the antigenic
component involved or even if antigen is present.
In the present study efforts were made both to use established
methods with or without modification and also to develop a new and
sensitive method for the detection and quantitation of soluble immune
complexes in the sera of patients with thyroid disorders or with
diabetes mellitus.
At the initiation of this study few of the available methods were
thought to be sufficiently sensitive. The method of inhibition of
antibody-dependent cell-mediated cytotoxicity (ADCC) which was described
by Jewell and MacLennan (1973) to detect immune complexes in the sera
of patients with inflammatory bowel disease appeared to be the most
sensitive and reproducible. A modification of this method was under
trial in this laboratory in which chicken red blood cells were
substituted for the Chang liver cells used as target cells in the Jewell
and MacLennan assay. The variable results obtained using different
samples of human lymphocytes as effector cells together with the
difficulties encountered in obtaining a regular supply of human blood
prompted the development of a further modification using other
lymphocytes as effector cells. Rat spleen lymphocytes were found to
be effective in inducing antibody-dependent cell-mediated cytotoxicity
and were used in this study in an inhibition assay for the detection
of immune complexes.
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Using this assay it was possible to demonstrate a marked
inhibition of ADCC by the sera of patients with Hashimoto thyroiditis
and primary hypothyroidism and a less marked inhibition in the case
of thyrotoxic patients as compared with their age- and sex-matched
controls.
It is possible that this inhibition may be due not to the presence
of antigen-antibody complexes but to the presence of aggregated IgG
formed as a result of heat inactivation of the sera. Heat inactivation
was found to be necessary to prevent lysis of the target cells by
human serum in the absence of added antibody. This lysis could be
mediated either by natural antibody or by complement. The finding
that chicken serum lysed autologous erythrocytes would appear to
exclude the presence of natural antibody. The participation of target
cell-bound complement in cell-mediated cytotoxicity as reported by many
workers (Perlmann et al., 1969; O'Neill et al., 1973; Lustig and
Bianco, 1976) and suggested by the results of Eden and co-workers (1973)
and Scornik and Drewinko (1975), does not appear to be involved, since
the effect was also observed in the absence of lymphoid cells or in
the presence of cytochalasin B, an agent which effectively blocks
cell-mediated cytotoxicity (Gelfand et al., 1975). Consequently, it
is likely that the lysis was mediated directly by complement activated
by the chicken erythrocytes in a manner similar to that reported for
mouse spleen cells (Pepys, 1974), tumour cells (Okada and Baba, 1974),
rabbit cells (Platts-Mills and Ishizaka, 1974) and human and rabbit
platelets (Zimmerman and Kolb, 1976). The role of complement in
target cell lysis is clearly indicated by the observation that
complement activity and inhibitory activity could be separated by
Sephadex G-200 fractionation and that the inhibitory activity was
demonstrable in the absence of heat inactivation.
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The observed inhibition of ADCC by serum samples from patients with
thyroid disorders is thought more likely to be due to the presence of
immune complexes than to that of aggregated IgG. This was initially
suggested by the observation that the degree of inhibition did not
correlate with the levels of serum IgG. At a given amount of IgG in
both test sera and their controls there was still a significant
difference in the percentage of inhibition. Further evidence was
provided by the results of experiments in which serum samples were
fractionated on Sephadex G-200. These demonstrated that inhibitory
activity was localized predominantly in front of the ascending limb of
the IgG profile, and not in those fractions in which aggregated IgG
should appear. Heat inactivation of serum was in fact found to induce
the formation of aggregated IgG; sera which were heat-inactivated and
then fractionated by Sephadex G-200 showed the formation of inhibitory
material in the 19S peak. Thus it appears that the inhibition of
ADCC by heat-inactivated test sera is due to the presence of both
antigen-antibody complexes and aggregated IgG. The formation of
aggregates and their quantitation in heat-inactivated normal serum is
discussed below with respect to the RSL assay.
The sensitivity of the ADCC inhibition assay was found to be
around 250pg/ml in neat serum and it was felt that this degree of
sensitivity was insufficient to detect small amounts of immune complexes
in the test sera. Efforts to increase the sensitivity of the ADCC
inhibition assay by using a low effector to target cell ratio were
unsuccessful due to problems associated with higher levels of
inhibition by control sera. Further work was carried out to increase
the sensitivity of the assay and to circumvent the need for heat
inactivation (Barkas, Al-khateeb and Irvine, submitted for publication).
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In order to confirm and extend the data obtained in the ADCC
inhibition assay, experiments were carried out using the Clq deviation
test which was reported by Sobel and co-workers (1975) to be a more
sensitive and reproducible method for the detection of immune complexes.
These workers described a new method based on the deviation of
radiolabelled Clq from binding to sensitized s~heep red blood cells.
According to these authors, the sensitivity of the assay was very high
in the sense that it could detect very minute amounts of complexes.
In the present study this assay was found to be moderately sensitive
in detecting aggregated IgG in medium but not in the detection of
aggregates added to serum samples at levels less than approximately
100pg/ml. It is likely that this lack of sensitivity was due to the
fact that aggregates were already present in the sera as a consequence
of heat inactivation. The sensitivity of the assay with respect to
added aggregates was found to vary markedly from one sample of normal
human serum to another.
Many of the difficulties encountered with these two techniques
may be attributed to the need to heat-inactivate sera before testing
for the presence of immune complexes. During the progress of this
work, a new method for the detection of complexes was reported in which
heat inactivation was not required. Iheofilopolous and co-workers
(197Aa) screened different lymphoblastoid cell lines for the presence
of membrane-bound Ig and receptors for IgG Fc and complement in order
to find a suitable model for measuring the binding of immune complexes.
They found that Raji cells were the most suitable as these cells
lacked membrane bound IgG and possessed receptors for IgG Fc, C3b and
C3d. Using these cells they developed a radioimmunoassay
(Theofilopolous et al., 1976) which is based on the binding of immune
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complexes via complement receptors and the subsequent detection of these
complexes using radiolabelled anti-human IgG. Using this technique
they reported the presence of immune complexes in a number of
pathological sera. Quantitation of the complexes was carried out by
referring to a standard curve of radiolabelled antibody uptake by
cells previously incubated with varying amounts of aggregated IgG in
normal human serum. This was based on the observation that aggregated
IgG possesses many of the properties of immune complexes in vitro
(Christian, 1960a; Ishizaka et_al., 1965).
In the present study, this assay was used to demonstrate and
quantitate immune complexes in the sera of patients with thyroid
disorders and diabetes. Among those patients with thyroid disorders,
the highest levels were detected in sera from patients with Hashimoto
thyroiditis while lesser amounts were found in the hypothyroid and
thyrotoxic groups. In patients with diabetes, immune complexes were
detected in the sera from juvenile insulin-dependent diabetics and from
insulin-treated diabetics but not in the sera from patients treated
with oral hypoglycaemic agents or by restriction of diet.
The sensitivity of the Raji cell radioimmunoassay was found to
be approximately 6pg/ml of added aggregated IgG, corresponding to
24p.g/ml in neat serum since all sera were used at a dilution of 1:4.
This level of sensitivity is lower than that reported by Theofilopolous
and co-workers, who were able to detect 1.6pg/ml (equivalent to 6pg/ml
in neat serum. This apparent difference in sensitivity could be due
to differences in the method of establishing the standard curve of
radioactivity, since Theofilopolous and co-workers used lower amounts
of IgG to be aggregated and subsequently added to 1:4 serum. However,
experiments using similar amounts of IgG to form aggregates did not
result in an increase in the sensitivity of the assay in the present
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study. Alternatively, the difference in sensitivity might be
attributed simply to the inherent variability associated with the
culture of cell lines in different laboratories.
The failure to detect complexes in certain sera from the thyroid
disorders and diabetes groups might be due either to the absence of
complexes in these sera or to the fact that the complexes exist in a
form unsuitable for detection in the Raji cell assay. Raji cells are
thought to bind large complexes formed in 2-6X antigen excess
(Theofilopolous et al., 1974b), and smaller complexes or those formed
in antibody excess may not be detected.
Raji cells have been shown to bind monomeric IgG as well as
aggregated IgG via their Fc receptors (Theofilopolous et al. , 1974b).
On this basis, the apparent detection of complexes in sera from the
Hashimoto group could be attributed to the presence of higher levels
of monomeric IgG in these sera as compared to their controls. In
order to eliminate this possibility, experiments were carried out in
which Fc receptors on Raji cells were blocked by incubation of these
cells with normal rabbit serum. This treatment was found to prevent
the binding of monomeric human IgG, contrary to the finding of
Theofilopolous and co-workers (1974b) who reported that rabbit IgG
did not bind to the Fc receptors on Raji cells. The observed
difference in binding between Hashimoto sera and their controls was
not affected by the use of cells pretreated with normal rabbit serum
in the Raji cell radioimmunoassay, and this would appear to rule out
the possibility that the higher levels of binding to Raji cells by
Hashimoto sera were due to high levels of monomeric IgG in these sera.
The Raji cell radioimmunoassay was used in an attempt to
characterize the antigenic component of the complexes detected in the
sera from patients with thyroid disorders. Using radiolabelled anti-
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human thyroglobulin antibody instead of radiolabelled anti-IgG
antibody, it was possible to demonstrate significantly higher levels
of binding of label to cells incubated with one third of the sera
scored positive for the presence of complexes. This result indicates
that in at least a proportion of these sera, the complexes present
contain thyroglobulin or other antigens which react with antibody to
thyroglobulin. The significance of this finding is discussed below.
A new and sensitive method for the detection of soluble complexes
was developed during this study. This method is a radioimmunoassay
using rat spleen leucocytes, and is based on the ability of these
cells to bind complexes via Fc receptors and the subsequent detection
of the IgG in the complexes by radiolabelled anti-human IgG. By
referring to a standard curve of radiolabelled antibody uptake by
cells previously incubated with varying amounts of aggregated IgG in
EDTA-treated normal human serum, it is possible to estimate the amount
of complexes in test sera. The radiolabelled antibody uptake was
found to be proportional to the amount of aggregates added to the
serum or medium. The amount of soluble complexes present in Lest
sera was equated to an amount of aggregated IgG on the standard curve
and expressed as pg aggregated IgG equivalents/ml.
The binding of aggregated IgG to RSL in medium was comparable to
that in EDTA-inactivated serum. This indicates that the binding was
mediated by Fc receptors and not complement receptors, possibly due
to the presence of more Fc receptors than complement receptors or to
the higher binding affinity of Fc receptors. The presence of
complement activity was found to inhibit the binding of aggregates
and also to induce the release of aggregates bound to RSL. The
inactivation of serum samples by treatment with EDTA but not with
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EGTA abolished this inhibitory activity, suggesting that complement
was acting via the alternative pathway. Similar findings have been
reported by Miller and co-workers (1973, 1974) for mouse lymphocytes
and platelets. These authors also showed that complement serves as a
sensitive regulator of the interaction between immune complexes and
cell membranes.
The binding of label to RSL incubated with aggregated IgG in
serum was slightly greater than that in medium, possibly due to the
non-specific binding of small amounts of monomeric IgG to the cells.
It was found that the uptake of label after the addition of 10mg/ml
monomeric IgG to RSL was equivalent to that observed after the addition
of 4}ig/ml of aggregated IgG. Although this indicates that small
amounts of monomeric IgG can bind to RSL, it is also possible that
this finding may be attributed to the presence of small amounts of
aggregates in the preparation of IgG used. The addition of 10mg/ml
monomeric IgG to sera containing complexes did not significantly
increase the binding of label to the cells. If it is assumed that
differences in IgG levels among different human sera are unlikely to be
much greater than 10mg/ml, this would appear to rule out the
possibility that the higher levels of binding detected by this assay
are due to the presence of monomeric IgG. In addition, only small
differences in the uptake of label were detected using a wide range of
normal human sera.
RSL have previously been used to detect immune complexes by the
inhibition of ADCC (Barkas et al., 1976). The sensitivity for the
detection of aggregates has subsequently been increased to 0.6pg/ml
in medium or 6pg/ml in serum (Barkas, Al-khateeb and Irvine, submitted
for publication). The RSL radioimmunoassay has considerable
advantages over this technique, being extremely simple and rapid to
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perform and also somewhat more sensitive to the presence of aggregates
in serum. The assay is also considerably simpler than the rather
similar assay using Raji cells. A further advantage over the Raji
cell radioimmunoassay is that the maintenance of a cell-line in culture
is not required.
The RSL radioimmunoassay was used to detect and quantitate
complexes in those serum samples used for the Raji cell assay.
Complexes were found in a higher percentage of sera from patients with
thyroid disorders or diabetes using the RSL assay than using the Raji
cell assay. This may be due to the higher sensitivity of the RSL
assay which allows the detection of 4pg/ml aggregated IgG in neat serum.
In the Raji cell radioimmunoassay it was necessary to dilute the test
serum to 1:A in order to minimise the inhibitory effect of complement
on the binding of aggregates to these cells (Theofilopolous et al.,
1976), and the limit of detection was 6pg/ml aggregated IgG (equivalent
to 2Apg/ml aggregates in neat serum). In general, the amount of
complexes detected in a given serum was higher by the Raji cell method,
possibly reflecting the different modes of binding in the two methods.
Binding to the Raji cells is mediated by complement receptors and to
a lesser extent by Fc receptors whereas binding to the RSL is via Fc
receptors alone, as indicated by the similar levels of binding of
aggregates in medium or EDTA-treated serum.
One' possible factor which could give rise to spurious results in
the RSL assay is the presence, in the sera tested, of IgG antibodies to
rat erythrocytes or leucocytes. Anti-rat erythrocyte antibodies in
human sera have been described by McDonald (1973) and by Salaman and
co-workers (1975), who also mentioned the presence of anti-leucocyte
antibodies. These authors suggested that these antibodies arise
probably as a consequence of previous infection by gram-negative
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bacteria, since they have been found to cross-react with these bacteria.
In the RSL experiments, the presence of anti-rat erythrocyte antibodies
was demonstrated by haemagglutination. Antibody activity was,
however, completely abolished by one absorption with rat erythrocytes.
It appears that any IgG antibodies to rat leucocytes are also removed
by this single absorption, since further absorption using rat
thymocytes did not significantly decrease the amount of binding to
RSL in the assay system. In addition, no differences in binding of
radiolabelled anti-human IgG antibody to rat thymocytes were detected
among sera of patients or controls after one absorption with rat
erythrocytes. A final argument against the possible influence of
anti-rat antibodies in the RSL assay is the demonstration of complete
inhibition of the binding by prior treatment of the RSL with aggregated
autologous rat IgG, demonstrating that binding does indeed occur via
the Fc receptors.
It has been repeatedly suggested that heating serum at 56°C for
30 min in order to inactivate the complement could lead to the
formation of aggregates (Zubler et al., 1976a; WHO Scientific Group,
1977), and that this could influence assays for immune complexes,
although little evidence for this has been presented. In the present
study, it has been shown that heating serum induces the formation of
aggregates detectable by the ADCC inhibition assay. Furthermore,
using the RSL assay it was possible to quantitate these aggregates.
Up to 128pg equivalents of aggregated IgG were detected in heated
sera.
The RSL assay has a number of important advantages over other
methods used for the detection of immune complexes. In contrast to
the ADCC inhibition assay and those methods using Clq, heat
inactivation of sera is not required. The sensitivity of the RSL
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radioimmunoassay is significantly greater than that of other new
methods proposed for the detection of soluble immune complexes. For
example, the selective precipitation by polyethylene glycol of
radiolabelled C1q bound to complexes (Zubler et al.. 1976a) detects
aggregated IgG at a minimum concentration of approximately I00pg/ml.
In the present study, the Raji cell assay was found to detect 24pg/ml
added aggregates in normal human serum. In addition, the use of an
assay in which the binding of complexes is mediated through Fc receptors
is to be preferred to one which involves binding through complement
receptors since in the latter case the binding is influenced by the
amount of complement fixed to the complexes, which in turn depends on
the size of the complexes (Christian, 1960; Ishizaka et al., 1965;
Agnello et al., 1970). Moreover, not all the subclasses of IgG fix
complement with the same affinity. IgG^ and IgG^ are more effective
in this respect than IgG£ and IgG^ (Augener et al., 1971).
Using the ADCC inhibition assay, the Raji cell radioimmunoassay
and the RSL radioimmunoassay, it was possible to demonstrate the
presence of immune complexes in the sera of patients with thyroid
disorders. The greatest frequency was observed in sera from patients
with Hashimoto thyroiditis. In addition, using the Raji cell assay
it was possible to demonstrate the presence of thyroglobulin in
44% of the Hashimoto sera scored positive for the presence of immune
complexes and in 30% of the positive hypothyroid sera. The earlier
study of Calder and co-workers (1974) using the anti-complementary
assay also detected immune complexes in sera of patients with thyroid
diseases, but no attempt was made to identify the antigenic component
involved. The apparent absence of thyroglobulin in the remaining
positive sera suggests either that other antigens may be involved or
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that the thyreoglobulin antigenic determinants are inaccessible.
Alternatively, the assay used in this study may be insufficiently
sensitive. Recently, Takeda and Kriss (1977) demonstrated a
radiometric two-site assay for soluble thyroglobulin-anti-thyroglobulin
complexes applicable to human sera. Their preliminary data indicated
that thyroglobulin-antibody complexes were detected in the sera of 7
out of 29 patients with Graves' disease but not in the sera of 10
normal subjects.
It should be noted that the increased binding of labelled anti-
human thyroglobulin antibody to cells incubated with positive sera
demonstrated in this study may reflect the presence in the complexes
not of thyroglobulin but of thyroxine. All the Hashimoto and
hypothyroid patients in which the detected complexes were found to
contain thyroglobulin were on thyroxine, and it has been reported that
anti-thyroglobulin antibodies in mice, guinea pigs and rabbits are able
to bind thyroxine (McKenzie and Haibach, 1967; Margherita and
Premachandra, 1969).
The role of detected complexes in the pathogenesis of autoimmune
thyroid disease is uncertain. In the present study, thyroglobulin
was shown to be a constituent of the detected complexes in a proportion
of sera. Circulating thyroglobulin has been detected in the sera of
normal individuals (Hjort and Pedersen, 1962; Assem, 1964; Roitt and
Torrigiani, 1967; Torrigiani et al., 1969; Van Herle et_al., 1972).
It is possible that the deposition in the thyroid tissue of complexes
formed from thyroglobulin and specific antibody induces an inflammatory
response and the subsequent destruction of thyroid tissue. These
complexes may form in the circulation and then subsequently be
deposited in organs other than the thyroid gland. A significant
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correlation between the presence of thyroid disease and the involvement
of other organs has been reported. A high incidence of pernicious
anaemia, idiopathic hypoparathyroidism, diabetes mellitus and idiopathic
Addisons disease has been found in patients with thyroid disorders
(Irvine, 1967; Rose, 1974). Bloch and co-workers (1960) reported
that Sjogren's syndrome was associated with high titres of antibody to
thyroglobulin. One might speculate that the presence of circulating
immune complexes may be a common cause for multiple lesions in some
patients with autoimmune disease, but there is no evidence for such a
presumption.
The deposition of complexes on the surface of thyroid epithelial
cells may render the cells susceptible to antibody-dependent cell-
mediated cytotoxicity. It has been demonstrated by Calder and co¬
workers (1973c) that lymphoid cells from normal donors are rendered
cytotoxic to target cells coated with thyroglobulin and preincubated
with serum samples from patients with thyroid disorders. These
authors also reported a significant correlation between this cytotoxicity
and the serum antibody titre, although Wasserman and co-workers (1974)
were unable to demonstrate such a correlation. It was found in the
present study that there was no correlation between the presence or
titre of anti-thyroid antibodies and the presence or quantity of
immune complexes.
The presence of immune complexes in the circulation was not
associated with immune complex diseases such as arteritis or
glomerulonephritis and the presence of these complexes may be merely
a physiological phenomenon with no pathological significance. An
alternative explanation for the lack of pathogenic effect is that
these complexes may not beof a size suitable for deposition in vessel
walls or tissues. Cochrane (1971) reported that only large complexes
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(greater than 19S) were found in the vessel walls. The observation
in the present study that complexes in the sera of patients with
thyroid disorders are detected in front of the ascending limb of the
IgG profile on Sephadex G-200 fractionation may indicate that these
complexes are not of a suitable size for deposition. This finding
does not mean necessarily that larger complexes are not deposited in
the thyroid gland or in other tissue, since the presence of small
complexes in serum might be reflecting the presence of injurious
complexes that are deposited elsewhere (WHO Scientific Group, 1977).
It is worthy of note that even in rheumatoid arthritis, a disease in
which immune complexes play an important role, there is a striking
absence of nephritis in most patients. Accordingly, the absence of
an association between thyroid diseases and nephritis does not rule
out the possibility that immune complexes are involved in the
pathogenesis of thyroid disease. If complexes have no role in the
production of thyroid lesions, then the demonstration of complement
components Clq and C3 and of IgG, IgM and IgE in thyrotoxic glands
(Werner et al., 1972) together with the presence of electron dense
depositis in the follicular basement membranes of Hashimoto thyroid
glands and the high cytotoxic activity of lymphoid cells obtained from
Hashimoto patients (Calder et al., 1973b) are phenomena which require
some explanation.
Further studies on immune complexes in thyroid disorders are
required in order to further characterize the antigenic components in
the detected complexes. More sensitive methods for the detection of
thyroglobulin, such as the two-site radiometric assay (Takeda and Kriss,
1977), could be applied to this problem and these techniques could also
be exploited to detect other antigenic components. Separation of
complexes from pathological sera could be achieved using the Raji cell
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or RSL assays to bind these complexes followed by elution of the
complexes from the cells. These complexes could then be injected
into experimental animals in order to define the clinical and
histological changes, if any, induced by such complexes. The presence
of complexes in the sera of patients with Hashimoto thyroiditis or
primary hypothyroidism could be studied both before and after treatment
with thyroxine in order to define any differences in the quantity or
quality of these complexes.
Using the Raji cell radioimmunoassay, it was possible to
demonstrate the presence of soluble immune complexes in 24 out of 45
sera from patients with newly diagnosed insulin-dependent diabetes or
insulin-treated diabetes, compared with only 2 out of 45 age- and sex-
matched controls. The percentage of positive sera from diabetic
patients treated with oral hypoglycaemic agents or diet restriction
was similar to that of their age- and sex-matched controls. These
results were confirmed using the more sensitive RSL radioimmunoassay.
In newly diagnosed insulin-dependent diabetics, there was a
close correlation between the presence of soluble complexes and islet
cell antibodies, while no such correlation was apparent between the
presence of complexes and anti-viral antibodies. There was some
indication that anti-Coxsackie B4 virus antibodies tended to occur in
a high percentage of diabetic sera as compared to their age- and sex-
matched controls, but the prevalence and titres of antibodies to other
viruses were comparable in both diabetic and control groups. Similar
findings were reported by Gamble and co-workers, who found that
insulin-dependent diabetics within 3 months of onset had higher
antibody titres to Coxsackie viruses, particularly B4, than either
normal subjects or patients with diabetes of longer duration (Gamble
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et al. , 1969, 1973). The possible role of Coxsackie B4 virus in
inducing diabetes is not clear, although it has been reported that the
virus can induce necrotic lesions in the pancreas (Kibrick and
Benirschke, 1958) and that it may be isolated from the pancreas of
patients with pancreatitis (Fechner et al., 1963; Murphy and Simmul,
1964).
The correlation between the presence of complexes and islet cell
antibodies in sera from newly diagnosed diabetics suggests that the
antigens involved in these immune complexes may be derived from islet
cells. These antigens may be present in the circulation either through
a recent release of islet cell antigens or because they are being
continually released after the onset of clinical diabetes, The fact
that the symptoms of diabetes were present before diagnosis for as
long as 4 months in patients found to have immune complexes at the
time of diagnosis supports the latter alternative. The continuous
release of antigen from islet cells might be due to a slow inflammatory
process in the pancreatic B cells. These cells have been found to
persist after the clinical onset of this type of diabetes as evidenced
by their ability to produce C peptide (Heding and RasmusSen, 1975).
Islet cell antibody has been shown to react with all islet cells
although only B cells are markedly affected (Doniach, 1974; Egeberg
et al., 1976). Similarly, complexes deposited in the islets may
affect only B cells, although they may also affect the A and D cells
which possibly have greater powers of regeneration. Islet cell
antibodies were also found in the sera from two insulin-treated
diabetics and one patient treated with oral hypoglycaemic agents.
The fact that these three sera were found to contain complexes supports
the concept of a correlation between the presence of islet cell
antibodies and immune complexes. Detected complexes comprising islet
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cell antigen and antibody could be important in relation to antibody-
dependent cell-mediated cytotoxicity, with cytotoxic cells being
specifically armed by such complexes. On the other hand the presence
of complexes in newly diagnosed juvenile diabetics may have no
pathological significance and may be merely a consequence of islet
cell damage.
Soluble immune complexes were also detected and quantitated in
insulin-treated diabetics. These complexes most probably result from
treatment with heterologous insulin. A correlation was observed
between high titres of insulin antibodies and the presence of immune
complexes. The failure to detect complexes in some sera with low or
moderate levels of insulin antibodies may be due to technical reasons
or to the varying affinities that insulin antibodies may have in
different patients (Dixon et al. , 1975). Alternatively, immune
complexes present in these sera might be removed from the circulation
more rapidly than in other sera.
It was found that anti-insulin antibody titres appeared to be a
characteristic of the patient rather than of the dosage or duration of
insulin therapy. In this connection, it is worth noting that patients
on insulin treatment who are HLA.BW'15 tend to have higher titres of
insulin antibodies than patients of other HLA types (Bertrams et al..
1976). This might suggest that certain patients with insulin-dependent
diabetes might have a greater tendency than others to form complexes,
and this could be an appropriate subject for further study.
The possibility exists that late complications of diabetes may be
related, at least in part, to the production of immune complexes. It
is therefore noteworthy that juvenile-onset insulin-dependent diabetics
tended to have more immune complexes in relation to moderate or low
titres of insulin antibodies than did subjects who developed insulin-
UO
dependent diabetes after the age of 30 years, even though the duration
of diabetes and of insulin treatment was comparable in the two groups.
Insulin-dependent diabetes developing in young people is considered to
be associated with a greater risk of severe late diabetic complications
(Bradley and Ramos, 1971). It is possible that this is due to
differences in the size of complexes formed in these two groups.
Complexes of intermediate size appear to be the most injurious. Small
complexes do not bind complement, while larger complexes are rapidly
removed from the circulation (Cochrane and Koffler, 1973). Less severe
late diabetic complications do occur in mainly elderly patients with
maturity-onset diabetes who have received no insulin (Ortved Andersen,
1976). Taken together with the findings in this study that few
patients on oral hypoglycaemic agents or diet restriction have
complexes, this would suggest that complications can develop in the
absence of complexes.
The presence of circulating soluble complexes in sera of insulin-
dependent diabetics may reflect the presence of complexes deposited in
the tissues'. Both insulin and anti-insulin antibodies have been
detected in the renal glomeruli of diabetics with nephropathy (Berns
et al., 1962; Farrant and Shedden, 1965)- Insulin-binding capacity
has also been demonstrated in the vessels of the diabetic eye (Coleman
et al., 1962). Bloodworth (1968) reported the presence of fine
granular deposits in the renal tissue of diabetics resembling those
found in certain types of glomerulonephritis. It was found in the
present study that after prolonged insulin therapy there is a tendency
for immune complexes to occur. Since insulin treatment has to be
continued for at least 10 years before clinical complications manifest
themselves, it is likely that the formation of complexes is a
relatively slow process and that the progressive accumulation of these
U1
complexes in different tissues over a long period of time leads to the
appearance of complications. Westberg and Michael (1972) demonstrated
that the basement membrane in diabetic glomerulosclerosis contains
not only insulin, IgG, IgM and components of complement but also "non-
immunological" serum proteins deposited in linear fashion. Such a
finding suggests that there may be non-specific lesions involving the
trapping of serum proteins.
Further work on the extent to which soluble immune complexes
are implicated in the pathogenesis of juvenile insulin-dependent
diabetes is required. It was found in the present study that six
newly-diagnosed juvenile diabetics, had titres of Coxsackie B4
antibodies greater than or equal to 1:32, but only three of these had
evidence of immune complexes in their serum. Studies involving
larger numbers of newly-diagnosed juvenile diabetics may reveal a
significant correlation between the presence of complexes and the
presence of viral antibodies. It is of great importance not only to
detect complexes but also to determine the antigenic component(s)
involved. This could be acheived by a modification of the Raji cell
or RSL radioimmunoassay using radiolabelled anti-viral antibodies and
radiolabelled anti-islet cell antibodies. Further studies should be
undertaken in order to define the pathological role of the complexes
formed when diabetic patients are treated with insulin. The use of
highly purified insulin in the treatment of diabetics has been
reported not to induce a significant increase in serum antibodies
(Ortved Andersen, 1975). A comparative study of patients treated
with highly purified insulin or with crude insulin might reveal
differences in the levels of complexes in the sera of these two groups
of patients and subsequent differences in the development of
complications.
U2
The development of sensitive and reproducible methods for the
detection of circulating immune complexes which avoid the use of
living cells or unstable molecules, do not require heat inactivation
of sera and which are capable of processing large numbers of sera,
is likely to be of paramount importance in future work on the
presence and role of antigen-antibody complexes in disease.
A number of such techniques have recently been reported or are
currently under trial. These include assays involving the use of
bovine conglutinin (Eisenberg et al., 1977; Casali et al. , 1977)
and latex particles with low affinity IgM antibodies (Levinsky and
Soothill, 1977) and a modified solid phase Clq radioimmunoassay (Hay
Nineham and Roitt, personal communication). The application of one or
more of these methods to the testing of serum samples from patients
with thyroid disorders or diabetes may prove to be of great value.
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APPENDIX II
PREPARATION OF BUFFERS




Made up to 1 litre with distilled water
2. 0.1M phosphate buffer pH7
KH2P0a 5-3g
K2HP0^ 10.6g
Made up to 1 litre with distilled water
3. 0.5M phosphate buffer pH8
945ml 0.5M K2HP0^ (87g/litre)
55ml 0.5M KH2P0^ (68g/litre)
4. Complement fixation diluent (OED) pH7.2





Made up to 1 litre with distilled water
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